Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Search

Page Path
HOME > Search
39 "Neoplasm metastasis"
Filter
Filter
Article category
Keywords
More +
Publication year
More +
Authors
More +
Funded articles
More +
Original Articles
Lung and Thoracic cancer
MLL4 Regulates the Progression of Non–Small-Cell Lung Cancer by Regulating the PI3K/AKT/SOX2 Axis
Yang Yang, Rongfang Qiu, Qiaoyou Weng, Ziwei Xu, Jingjing Song, Siyu Zhao, Miaomiao Meng, Dengke Zhang, Chunli Kong, Hailin Wang, Min Xu, Zhongwei Zhao, Jiansong Ji
Cancer Res Treat. 2023;55(3):778-803.   Published online January 26, 2023
DOI: https://doi.org/10.4143/crt.2022.1042
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Mixed-lineage leukemia protein 4 (MLL4/KMT2D) is a histone methyltransferase, and its mutation has been reported to be associated with a poor prognosis in many cancers, including lung cancer. We investigated the function of MLL4 in lung carcinogenesis.
Materials and Methods
RNA sequencing (RNA-seq) in A549 cells transfected with control siRNA or MLL4 siRNA was performed. Also, we used EdU incorporation assay, colony formation assays, growth curve analysis, transwell invasion assays, immunohistochemical staining, and in vivo bioluminescence assay to investigate the function of MLL4 in lung carcinogenesis.
Results
We found that MLL4 expression was downregulated in non–small cell lung cancer (NSCLC) tissues compared to adjacent normal tissues and tended to decrease with disease stage progression. We analyzed the transcriptomes in control and MLL4- deficient cells using high-throughput RNA deep sequencing (RNA-seq) and identified a cohort of target genes, such as SOX2, ATF1, FOXP4, PIK3IP1, SIRT4, TENT5B, and LFNG, some of which are related to proliferation and metastasis. Our results showed that low expression of MLL4 promotes NSCLC cell proliferation and metastasis and is required for the maintenance of NSCLC stem cell properties.
Conclusion
Our findings identify an important role of MLL4 in lung carcinogenesis through transcriptional regulation of PIK3IP1, affecting the PI3K/AKT/SOX2 axis, and suggest that MLL4 could be a potential prognostic indicator and target for NSCLC therapy.

Citations

Citations to this article as recorded by  
  • Role and potential therapeutic value of histone methyltransferases in drug resistance mechanisms in lung cancer
    Linxiang Zhang, Xueying Zhang, Yan Shi, Yuhan Ni, Jiaojiao Fei, Zhixin Jin, Wenjuan Li, Xiaojing Wang, Nan Wu
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • The multifaceted role of SOX2 in breast and lung cancer dynamics
    Kiavash Hushmandi, Seyed Hassan Saadat, Seyedalireza Mirilavasani, Salman Daneshi, Amir Reza Aref, Noushin Nabavi, Rasoul Raesi, Afshin Taheriazam, Mehrdad Hashemi
    Pathology - Research and Practice.2024; 260: 155386.     CrossRef
  • PIK3IP1: structure, aberration, function, and regulation in diseases
    Yingjie Jia, Pengxing He, Xubin Ma, Kaili Lv, Ying Liu, Yichao Xu
    European Journal of Pharmacology.2024; 977: 176753.     CrossRef
  • UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer cell by regulating PI3K/AKT pathway
    Li He, Heng Chen, Bin Ruan, Li He, Ming Luo, Yulun Fu, Rui Zou
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Role of histone methyltransferase KMT2D in BMSC osteogenesis via AKT signaling
    Zhichun Zhang, Yanyan Guo, Xuejun Gao, Xiaoyan Wang, Chanyuan Jin
    Regenerative Therapy.2024; 26: 775.     CrossRef
  • Landscape of targeted therapies for lung squamous cell carcinoma
    Qiuxuan Chen, Xiaoshuo Zheng, Weiting Cheng, Jian Li
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • 4,576 View
  • 277 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Breast cancer
Diagnostic Assessment of Deep Learning Algorithms for Frozen Tissue Section Analysis in Women with Breast Cancer
Young-Gon Kim, In Hye Song, Seung Yeon Cho, Sungchul Kim, Milim Kim, Soomin Ahn, Hyunna Lee, Dong Hyun Yang, Namkug Kim, Sungwan Kim, Taewoo Kim, Daeyoung Kim, Jonghyeon Choi, Ki-Sun Lee, Minuk Ma, Minki Jo, So Yeon Park, Gyungyub Gong
Cancer Res Treat. 2023;55(2):513-522.   Published online September 6, 2022
DOI: https://doi.org/10.4143/crt.2022.055
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Assessing the metastasis status of the sentinel lymph nodes (SLNs) for hematoxylin and eosin–stained frozen tissue sections by pathologists is an essential but tedious and time-consuming task that contributes to accurate breast cancer staging. This study aimed to review a challenge competition (HeLP 2019) for the development of automated solutions for classifying the metastasis status of breast cancer patients.
Materials and Methods
A total of 524 digital slides were obtained from frozen SLN sections: 297 (56.7%) from Asan Medical Center (AMC) and 227 (43.4%) from Seoul National University Bundang Hospital (SNUBH), South Korea. The slides were divided into training, development, and validation sets, where the development set comprised slides from both institutions and training and validation set included slides from only AMC and SNUBH, respectively. The algorithms were assessed for area under the receiver operating characteristic curve (AUC) and measurement of the longest metastatic tumor diameter. The final total scores were calculated as the mean of the two metrics, and the three teams with AUC values greater than 0.500 were selected for review and analysis in this study.
Results
The top three teams showed AUC values of 0.891, 0.809, and 0.736 and major axis prediction scores of 0.525, 0.459, and 0.387 for the validation set. The major factor that lowered the diagnostic accuracy was micro-metastasis.
Conclusion
In this challenge competition, accurate deep learning algorithms were developed that can be helpful for making a diagnosis on intraoperative SLN biopsy. The clinical utility of this approach was evaluated by including an external validation set from SNUBH.

Citations

Citations to this article as recorded by  
  • Comparing the diagnostic efficacy of optical coherence tomography and frozen section for margin assessment in breast-conserving surgery: a meta-analysis
    Shishun Fan, Huirui Zhang, Zhenyu Meng, Ang Li, Yuqing Luo, Yueping Liu
    Journal of Clinical Pathology.2024; 77(8): 517.     CrossRef
  • Intraoperative Margin Assessment in Breast Conservation Surgery: A Necessity or a Luxury?
    Srijan Shukla, Nisha Hariharan
    Annals of Surgical Oncology.2023; 30(9): 5314.     CrossRef
  • 6,236 View
  • 203 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Analysis of PIK3CA Mutation Concordance and Frequency in Primary and Different Distant Metastatic Sites in Breast Cancer
Jieun Park, Soo Youn Cho, Eun Sol Chang, Minjung Sung, Ji-Young Song, Kyungsoo Jung, Sung-Su Kim, Young Kee Shin, Yoon-La Choi
Cancer Res Treat. 2023;55(1):145-154.   Published online April 20, 2022
DOI: https://doi.org/10.4143/crt.2022.001
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the concordance rate of PIK3CA mutations between primary and matched distant metastatic sites in patients with breast cancer and to verify whether there are differences in the frequency of PIK3CA hotspot mutations depending on the metastatic sites involved.
Materials and Methods
Archived formalin-fixed paraffin-embedded (FFPE) specimens of primary breast and matched distant metastatic tumors were retrospectively obtained for 49 patients. Additionally, 40 archived FFPE specimens were independently collected from different breast cancer metastatic sites, which were limited to three common sites: the liver, brain, and lung. PIK3CA mutations were analyzed using droplet digital PCR, including hotspots involving exons 9 and 20.
Results
After analysis of 49 breast tumors with matched metastasis sites, 87.8% showed concordance in PIK3CA mutation status. According to PIK3CA hotspot mutation testing in 89 cases of breast cancer metastatic sites, the proportion of PIK3CA mutations at sites of metastasis involving the liver, brain, and lung was 37.5%, 28.6%, and 42.9%, respectively, which did not result in statistical significance.
Conclusion
The high concordance of PIK3CA mutation status between primary and matched metastasis sites suggests that metastatic sites, regardless of the metastatic organ, could be considered sample sources for PIK3CA mutation testing for improved therapeutic strategies in patients with metastatic breast cancer.

Citations

Citations to this article as recorded by  
  • Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer
    Yue Wang, Xin Li, Shuang Zhang, Li Liang, Ling Xu, Yinhua Liu, Ting Li
    Japanese Journal of Clinical Oncology.2024; 54(9): 1024.     CrossRef
  • Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis
    Justus Rosin, Ella Svegrup, Antonios Valachis, Ioannis Zerdes
    Breast Cancer Research and Treatment.2023; 201(2): 161.     CrossRef
  • Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer
    Konstantinos Venetis, Francesco Pepe, Elisabetta Munzone, Elham Sajjadi, Gianluca Russo, Pasquale Pisapia, Mariia Ivanova, Giuseppina Bonizzi, Davide Vacirca, Alessandra Rappa, Alberto Ranghiero, Sergio Vincenzo Taormina, Giuseppe Viale, Giancarlo Troncon
    Cells.2022; 11(22): 3545.     CrossRef
  • 6,418 View
  • 291 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer
Jung Sun Kim, Koung Jin Suh, Dae-Won Lee, Go-un Woo, Miso Kim, Se Hyun Kim, Han Suk Ryu, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, So Yeon Park, In Ae Park, Jee Hyun Kim, Seock-Ah Im
Cancer Res Treat. 2022;54(2):488-496.   Published online August 13, 2021
DOI: https://doi.org/10.4143/crt.2021.394
AbstractAbstract PDFPubReaderePub
Purpose
We aimed to assess the real-world efficacy of nab-paclitaxel in metastatic breast cancer patients.
Materials and Methods
This is a retrospective study performed in two tertiary referral hospitals in Korea. Patients with metastatic breast cancer treated with nab-paclitaxel (Abraxane®) between March 2016 and March 2020 were enrolled.
Results
A total of 102 patients with metastatic breast cancer were included. Patients were heavily pre-treated with a median of four prior lines of chemotherapy (5 lines when including endocrine therapy in hormone-receptor-positive patients), and 66 patients (64.7%) were exposed to taxanes in the metastatic setting. According to St. Gallen molecular subtypes, 36 patients (35.3%) were luminal A, 28 (27.5%) were luminal B, 18 (17.7%) were human epidermal growth factor receptor 2–positive and 20 (19.6%) had triple-negative disease. Fifty patients (49.0%) were treated with a 3-weekly regimen (260 mg/m2 on day 1 every 3 weeks), and 52 (51.0%) were treated with a weekly regimen (100 mg/m2 every week). Objective response rate was 22.9%. After a median follow-up of 22.0 months, median progression-free survival (PFS) was 4.0 months (95% confidence interval [CI], 2.6 to 4.8) and median overall survival was 8.7 months (95% CI, 7.5 to 11.2). Patients treated with weekly regimen had longer PFS compared to 3-weekly regimen (5.5 vs. 2.3 months, p < 0.001). Multivariate analysis revealed the treatment regimen as an independent prognostic factor for PFS. There was no grade 3 or 4 hypersensitivity reaction.
Conclusion
This real-world data shows that nab-paclitaxel is a reasonable treatment option in heavily pre-treated and/or taxane-exposed metastatic breast cancer patients.

Citations

Citations to this article as recorded by  
  • Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
    P. Meyer-Wilmes, J. Huober, M. Untch, J.-U. Blohmer, W. Janni, C. Denkert, P. Klare, T. Link, K. Rhiem, C. Bayer, M. Reinisch, V. Bjelic-Radisic, D.M. Zahm, C. Hanusch, C. Solbach, G. Heinrich, A.D. Hartkopf, A. Schneeweiss, P. Fasching, N. Filmann, V. Ne
    ESMO Open.2024; 9(5): 103009.     CrossRef
  • Real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and laboratory parameters in patients across metastatic tumor sites
    Vikas Talreja, Sangeeta Khetwani, Ethirajan Nanadagopal, Nilesh Eknath Borkar, Kunal Khobragade
    International Journal of Molecular and Immuno Oncology.2024; 9: 46.     CrossRef
  • Safety and efficacy of generic nab-paclitaxel-based therapy in Chinese patients with malignant tumors in a real-world setting: a multicenter prospective observational study
    Fei He, Yancai Sun, Wenzhou Zhang, Qiongshi Wu, Donghang Xu, Zaixian Bai, Zhiying Hao, Weiyi Feng, Kanghuai Zhang, Jiang Liu, Mei Dong, Guangxuan Liu, Guohui Li
    Discover Oncology.2024;[Epub]     CrossRef
  • Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study
    Zhichao Tian, Shuping Dong, Yang Yang, Shilei Gao, Yonghao Yang, Jinpo Yang, Peng Zhang, Xin Wang, Weitao Yao
    BMC Cancer.2022;[Epub]     CrossRef
  • Paclitaxel

    Reactions Weekly.2022; 1926(1): 383.     CrossRef
  • Natural Taxanes: From Plant Composition to Human Pharmacology and Toxicity
    Ľuboš Nižnanský, Denisa Osinová, Roman Kuruc, Alexandra Hengerics Szabó, Andrea Szórádová, Marián Masár, Žofia Nižnanská
    International Journal of Molecular Sciences.2022; 23(24): 15619.     CrossRef
  • A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity Against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma
    Hua Yang, Mu-Zi-he Zhang, Hui-wei Sun, Yan-tao Chai, Xiaojuan Li, Qiyu Jiang, Jun Hou
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • 7,306 View
  • 221 Download
  • 5 Web of Science
  • 7 Crossref
Close layer
Challenge for Diagnostic Assessment of Deep Learning Algorithm for Metastases Classification in Sentinel Lymph Nodes on Frozen Tissue Section Digital Slides in Women with Breast Cancer
Young-Gon Kim, In Hye Song, Hyunna Lee, Sungchul Kim, Dong Hyun Yang, Namkug Kim, Dongho Shin, Yeonsoo Yoo, Kyowoon Lee, Dahye Kim, Hwejin Jung, Hyunbin Cho, Hyungyu Lee, Taeu Kim, Jong Hyun Choi, Changwon Seo, Seong il Han, Young Je Lee, Young Seo Lee, Hyung-Ryun Yoo, Yongju Lee, Jeong Hwan Park, Sohee Oh, Gyungyub Gong
Cancer Res Treat. 2020;52(4):1103-1111.   Published online June 30, 2020
DOI: https://doi.org/10.4143/crt.2020.337
AbstractAbstract PDFPubReaderePub
Purpose
Assessing the status of metastasis in sentinel lymph nodes (SLNs) by pathologists is an essential task for the accurate staging of breast cancer. However, histopathological evaluation of sentinel lymph nodes by a pathologist is not easy and is a tedious and time-consuming task. The purpose of this study is to review a challenge competition (HeLP 2018) to develop automated solutions for the classification of metastases in hematoxylin and eosin–stained frozen tissue sections of SLNs in breast cancer patients.
Materials and Methods
A total of 297 digital slides were obtained from frozen SLN sections, which include post–neoadjuvant cases (n = 144, 48.5%) in Asan Medical Center, South Korea. The slides were divided into training, development, and validation sets. All of the imaging datasets have been manually segmented by expert pathologists. A total of 10 participants were allowed to use the Kakao challenge platform for six weeks with two P40 GPUs. The algorithms were assessed in terms of the AUC (area under receiver operating characteristic curve).
Results
The top three teams showed 0.986, 0.985, and 0.945 AUCs for the development set and 0.805, 0.776, and 0.765 AUCs for the validation set. Micrometastatic tumors, neoadjuvant systemic therapy, invasive lobular carcinoma, and histologic grade 3 were associated with lower diagnostic accuracy.
Conclusion
In a challenge competition, accurate deep learning algorithms have been developed, which can be helpful in making frozen diagnosis of intraoperative sentinel lymph node biopsy. Whether this approach has clinical utility will require evaluation in a clinical setting

Citations

Citations to this article as recorded by  
  • Diagnostic Assessment of Deep Learning Algorithms for Frozen Tissue Section Analysis in Women with Breast Cancer
    Young-Gon Kim, In Hye Song, Seung Yeon Cho, Sungchul Kim, Milim Kim, Soomin Ahn, Hyunna Lee, Dong Hyun Yang, Namkug Kim, Sungwan Kim, Taewoo Kim, Daeyoung Kim, Jonghyeon Choi, Ki-Sun Lee, Minuk Ma, Minki Jo, So Yeon Park, Gyungyub Gong
    Cancer Research and Treatment.2023; 55(2): 513.     CrossRef
  • Artificial intelligence and frozen section histopathology: A systematic review
    Benjamin G. Gorman, Mark A. Lifson, Nahid Y. Vidal
    Journal of Cutaneous Pathology.2023; 50(9): 852.     CrossRef
  • Effectiveness of transfer learning for enhancing tumor classification with a convolutional neural network on frozen sections
    Young-Gon Kim, Sungchul Kim, Cristina Eunbee Cho, In Hye Song, Hee Jin Lee, Soomin Ahn, So Yeon Park, Gyungyub Gong, Namkug Kim
    Scientific Reports.2020;[Epub]     CrossRef
  • 8,172 View
  • 202 Download
  • 14 Web of Science
  • 3 Crossref
Close layer
Clinical Implication of Concordant or Discordant Genomic Profiling between Primary and Matched Metastatic Tissues in Patients with Colorectal Cancer
Jung Yoon Choi, Sunho Choi, Minhyeok Lee, Young Soo Park, Jae Sook Sung, Won Jin Chang, Ju Won Kim, Yoon Ji Choi, Jin Kim, Dong-Sik Kim, Sung-Ho Lee, Junhee Seok, Kyong Hwa Park, Seon Hahn Kim, Yeul Hong Kim
Cancer Res Treat. 2020;52(3):764-778.   Published online February 16, 2020
DOI: https://doi.org/10.4143/crt.2020.044
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to identify the concordant or discordant genomic profiling between primary and matched metastatic tumors in patients with colorectal cancer (CRC) and to explore the clinical implication.
Materials and Methods
Surgical samples of primary and matched metastatic tissues from 158 patients (335 samples) with CRC at Korea University Anam Hospital were evaluated using the Ion AmpliSeq Cancer Hotspot Panel. We compared genetic variants and classified them as concordant, primary-specific, and metastasis-specific variants. We used a combination of principal components analysis and clustering to find genomic groups. Kaplan-Meier curves were used to appraise survival between genomic groups. We used machine learning to confirm the correlation between genetic variants and metastatic sites.
Results
A total of 282 types of deleterious non-synonymous variants were selected for analysis. Of a total of 897 variants, an average of 40% was discordant. Three genomic groups were yielded based on the genomic discrepancy patterns. Overall survival differed significantly between the genomic groups. The poorest group had the highest proportion of concordant KRAS G12V and additional metastasis-specific SMAD4. Correlation analysis between genetic variants and metastatic sites suggested that concordant KRAS mutations would have more disseminated metastases.
Conclusion
Driver gene mutations were mostly concordant; however, discordant or metastasis-specific mutations were present. Clinically, the concordant driver genetic changes with additional metastasis-specific variants can predict poor prognosis for patients with CRC.

Citations

Citations to this article as recorded by  
  • Gene-Mutation-Based Algorithm for Prediction of Treatment Response in Colorectal Cancer Patients
    Heather Johnson, Zahra El-Schich, Amjad Ali, Xuhui Zhang, Athanasios Simoulis, Anette Gjörloff Wingren, Jenny L. Persson
    Cancers.2022; 14(8): 2045.     CrossRef
  • Putative anoikis resistant subpopulations are enriched in lymph node metastases and indicate adverse prognosis in colorectal carcinoma
    Taneli T. Mattila, Madhura Patankar, Juha P. Väyrynen, Kai Klintrup, Jyrki Mäkelä, Anne Tuomisto, Pentti Nieminen, Markus J. Mäkinen, Tuomo J. Karttunen
    Clinical & Experimental Metastasis.2022; 39(6): 883.     CrossRef
  • Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project
    Youngwoo Lee, Soohyeon Lee, Jae Sook Sung, Hee-Joon Chung, Ah-reum Lim, Ju Won Kim, Yoon Ji Choi, Kyong Hwa Park, Yeul Hong Kim
    Cancer Research and Treatment.2021; 53(1): 123.     CrossRef
  • Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status
    Zhengquan Xu, Yanhong Ding, Wei Lu, Ke Zhang, Fei Wang, Guanxiong Ding, Jianqing Wang
    PeerJ.2021; 9: e11133.     CrossRef
  • High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer
    Seung Eun Lee, Ha Young Park, Dae-Yong Hwang, Hye Seung Han
    International Journal of Molecular Sciences.2021; 22(11): 5561.     CrossRef
  • Comprehensive Imaging Characterization of Colorectal Liver Metastases
    Drew Maclean, Maria Tsakok, Fergus Gleeson, David J. Breen, Robert Goldin, John Primrose, Adrian Harris, James Franklin
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • 8,407 View
  • 199 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Pretreatment Lymph Node Metastasis as a Prognostic Significance in Cervical Cancer: Comparison between Disease Status
Soo Young Jeong, Hyea Park, Myeong Seon Kim, Jun Hyeok Kang, E Sun Paik, Yoo-Young Lee, Tae Joong Kim, Jeong Won Lee, Byoung-Gie Kim, Duk Soo Bae, Chel Hun Choi
Cancer Res Treat. 2020;52(2):516-523.   Published online October 29, 2019
DOI: https://doi.org/10.4143/crt.2019.328
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Lymph node metastasis (LNM) is the most significant prognostic factor in cervical cancer that was recently incorporated into the International Federation of Gynecology and Obstetrics (FIGO) staging system. This study was performed to evaluate whether the prognostic significance of LNM differs according to disease status.
Materials and Methods
Patients with FIGO stage IB or higher cervical cancer who had pretreatment computed tomography and/or magnetic resonance imaging studies as well as long-term follow-up were enrolled in this retrospective study. The hazard ratio (HR) of Cox regression was used to determine the prognostic significance of LNM. The HRs were compared between the different tumor groups (based on stage, histology, tumor size, primary treatment, age, parametrium involvement, and lymphovascular space invasion).
Results
A total of 970 patients treated between January 1999 and December 2007 were included. The pretreatment LNM had prognostic significance in patients with stage IB1/IIA (HR for progression-free survival 2.10, p=0.001; HR for overall survival 1.99, p=0.005). However, the significance gradually decreased or disappeared with advancing stages. Similarly, the prognostic significance of the pretreatment LNM decreased with advancing disease status, including old age, parametrial involvement or lymphovascular space involvement. In contrast, the tumor size was associated with the prognostic significance of LNM with advancing status. The significance of the clinical LNM did not reflect the significance of the clinical stage. In contrast, the tumor size, parametrial involvement, and significance of the pathologic LNM reflected the clinical stage.
Conclusion
In patients with cervical cancer, pretreatment LNM on imaging has different clinical significance depending on the tumor status.

Citations

Citations to this article as recorded by  
  • Development of cervical intraepithelial neoplasia and invasive cervical cancer due to oxidative stress
    Amir Asotić, Memić Asotić, Muhamed Memić, Kerim Asotić, Amra Asotić
    Sanamed.2024; 19(1): 39.     CrossRef
  • Investigating and Analyzing Prognostic Factors and Their Impact on Recurrent Cervical Cancers
    Ashish Uke, Shweta B Dahake, Anurag Luharia, Monika Luharia, Gaurav V Mishra, Chanrashekhar Mahakalkar
    Cureus.2024;[Epub]     CrossRef
  • Based on 3D-PDU and clinical characteristics nomogram for prediction of lymph node metastasis and lymph-vascular space invasion of early cervical cancer preoperatively
    Shuang Dong, Yan-Qing Peng, Ya-Nan Feng, Xiao-Ying Li, Li-Ping Gong, Shuang Zhang, Xiao-Shan Du, Li-Tao Sun
    BMC Women's Health.2024;[Epub]     CrossRef
  • Recent Advances in Cervical Cancer Management: A Review on Novel Prognostic Factors in Primary and Recurrent Tumors
    Angela Santoro, Frediano Inzani, Giuseppe Angelico, Damiano Arciuolo, Emma Bragantini, Antonio Travaglino, Michele Valente, Nicoletta D’Alessandris, Giulia Scaglione, Stefania Sfregola, Alessia Piermattei, Federica Cianfrini, Paola Roberti, Gian Franco Za
    Cancers.2023; 15(4): 1137.     CrossRef
  • Identification of lymph node metastasis in pre‐operation cervical cancer patients by weakly supervised deep learning from histopathological whole‐slide biopsy images
    Qingqing Liu, Nan Jiang, Yiping Hao, Chunyan Hao, Wei Wang, Tingting Bian, Xiaohong Wang, Hua Li, Yan zhang, Yanjun Kang, Fengxiang Xie, Yawen Li, XuJi Jiang, Yuan Feng, Zhonghao Mao, Qi Wang, Qun Gao, Wenjing Zhang, Baoxia Cui, Taotao Dong
    Cancer Medicine.2023; 12(17): 17952.     CrossRef
  • Roles of DWI and T2-weighted MRI volumetry in the evaluation of lymph node metastasis and lymphovascular invasion of stage IB–IIA cervical cancer
    Y. Wang, X. Chen, H. Pu, Y. Yuan, S. Li, G. Chen, Y. Liu, H. Li
    Clinical Radiology.2022; 77(3): 224.     CrossRef
  • Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer
    Mu Xu, Xiaoyan Xie, Liangzhi Cai, Yongjin Xie, Qiao Gao, Pengming Sun
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Intravoxel Incoherent Motion (IVIM) MR Quantification in Locally Advanced Cervical Cancer (LACC): Preliminary Study on Assessment of Tumor Aggressiveness and Response to Neoadjuvant Chemotherapy
    Miriam Dolciami, Silvia Capuani, Veronica Celli, Alessandra Maiuro, Angelina Pernazza, Innocenza Palaia, Violante Di Donato, Giusi Santangelo, Stefania Maria Rita Rizzo, Paolo Ricci, Carlo Della Rocca, Carlo Catalano, Lucia Manganaro
    Journal of Personalized Medicine.2022; 12(4): 638.     CrossRef
  • The prognostic significance of pretreatment squamous cell carcinoma antigen levels in cervical cancer patients treated by concurrent chemoradiation therapy and a comparison of dosimetric outcomes and clinical toxicities between tomotherapy and volumetric
    Yuan-Kai Cheng, Shih-Hsun Kuo, Heng-Hsuan Yen, Jing-Hu Wu, Yu-Chieh Chen, Ming-Yii Huang
    Radiation Oncology.2022;[Epub]     CrossRef
  • What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer?
    Njål Lura, Kari S. Wagner-Larsen, David Forsse, Jone Trovik, Mari K. Halle, Bjørn I. Bertelsen, Øyvind Salvesen, Kathrine Woie, Camilla Krakstad, Ingfrid S. Haldorsen
    Insights into Imaging.2022;[Epub]     CrossRef
  • Clinical value of MRI, serum SCCA, and CA125 levels in the diagnosis of lymph node metastasis and para-uterine infiltration in cervical cancer
    Chao Ran, Jian Sun, Yunhui Qu, Na Long
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • A Novel Four-Gene Prognostic Signature as a Risk Biomarker in Cervical Cancer
    Jun Wang, Hua Zheng, Yatian Han, Geng Wang, Yanbin Li, Cuida Meng
    International Journal of Genomics.2020; 2020: 1.     CrossRef
  • 9,816 View
  • 223 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
The Feasibility of Spinal Stereotactic Radiosurgery for Spinal Metastasis with Epidural Cord Compression
Yi-Jun Kim, Jin Ho Kim, Kyubo Kim, Hak Jae Kim, Eui Kyu Chie, Kyung Hwan Shin, Hong-Gyun Wu, Il Han Kim
Cancer Res Treat. 2019;51(4):1324-1335.   Published online January 29, 2019
DOI: https://doi.org/10.4143/crt.2018.653
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to investigate the effectiveness and safety of spinal stereotactic radiosurgery (SRS) in treating spinal metastasis with epidural spinal cord compression (ESCC).
Materials and Methods
During 2013-2016, 149 regions of spinal metastasis in 105 patients treated with singlefraction (12-24 Gy) spinal SRS were reviewed. Cord compression of Bilsky grade 2 (with visible cerebrospinal fluid [CSF]) or 3 (no visible CSF) was defined as ESCC. Local progression (LP) and vertebral compression fracture (VCF) rates after SRS were evaluated using multivariate competing-risk regression analysis.
Results
The 1-year cumulative incidences of LP for Bilsky grades 0 (n=80), 1 (n=39), 2 (n=21), and 3 (n=9) were 3.0%, 8.4%, 0%, and 24.9%, respectively. Bilsky grade 2 ESCC did not significantly increase the LP rate (no LP for grade 2). The 1-year cumulative incidences of VCF for Bilsky grades 0, 1, 2, and 3 were 6.6%, 5.2%, 17.1%, and 12.1%, respectively. ESCC may increase VCF risk (subhazard ratio [SHR] for grade 2, 5.368; p=0.035; SHR for grade 3, 2.215; p=0.460). Complete or partial pain response rates after SRS were 79%, 78%, 53%, and 63% for Bilsky grades 0, 1, 2, and 3, respectively (p=0.008). No neurotoxicity of grade ≥ 3 was observed.
Conclusion
Spinal SRS for spinal metastasis with Bilsky grade 2 ESCC did not increase the LP rate, was not associated with severe neurotoxicity, and showed moderate VCF and pain response rates. Bilsky grade 3 had a high LP rate.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of SBRT for spine metastases: A systematic review and meta-analysis for preparation of an ESTRO practice guideline
    R.S. Guninski, F. Cuccia, F. Alongi, N. Andratschke, C. Belka, D. Bellut, M. Dahele, M. Josipovic, T.E. Kroese, P. Mancosu, G. Minniti, M. Niyazi, U Ricardi, P. Munck af Rosenschold, A. Sahgal, Y. Tsang, W.F.A.R. Verbakel, M. Guckenberger
    Radiotherapy and Oncology.2024; 190: 109969.     CrossRef
  • Metastatic Spinal Lesion with Minimal Epidural Compression: Surgical Treatment or Stereotactic Radiotherapy?
    O. I. Kit, D. E. Zakondyrin, A. A. Grin, E. E. Rostorguev, Y. V. Przhedetskiy, P. G. Sakun, V. I. Voshedskii, B. V. Matevosian, T. S. Shepelya
    Creative surgery and oncology.2024; 14(2): 127.     CrossRef
  • Surgical Interventions Following Radiotherapy in Spinal Metastases with Intermediate Instability: A Risk Factor Analysis: The Korean Society of Spinal Tumor Multicenter Study (KSST 2022-02)
    Se-Jun Park, Jin Ho Kim, Yong Chan Ahn, Woong Sub Koom, Hwa Kyung Byun, Young-Hoon Kim, Sang-Il Kim, Dong-Ho Kang
    Cancers.2024; 16(14): 2554.     CrossRef
  • Development of a novel 12-point grading system for evaluating epidural spinal cord compression and its clinical implications
    Xuyong Cao, Weihao Jiang, Xiongwei Zhao, Haikuan Yu, Mingxing Lei, Yuncen Cao, Xiuyun Su, Yaosheng Liu
    The Spine Journal.2023; 23(12): 1858.     CrossRef
  • Efficacy of Total En Bloc Spondylectomy versus Stereotactic Ablative Radiotherapy for Single Spinal Metastasis
    Dong-Ho Kang, Wooseok Lee, Bong-Soon Chang, Hyoungmin Kim, Sam Yeol Chang, Seong Hwa Hong, Jin Ho Kim, Hee Jung Son
    Cancers.2023; 15(23): 5518.     CrossRef
  • Radiomic modeling to predict risk of vertebral compression fracture after stereotactic body radiation therapy for spinal metastases
    Chengcheng Gui, Xuguang Chen, Khadija Sheikh, Liza Mathews, Sheng-Fu L. Lo, Junghoon Lee, Majid A. Khan, Daniel M. Sciubba, Kristin J. Redmond
    Journal of Neurosurgery: Spine.2022; 36(2): 294.     CrossRef
  • Stereotactic body radiotherapy for spinal metastases: a review
    Lanlan Guo, Lixin Ke, Ziyi Zeng, Chuanping Yuan, Ziwei Wu, Lei Chen, Lixia Lu
    Medical Oncology.2022;[Epub]     CrossRef
  • Treatment of Metastatic Spinal Disease; what the Radiologist needs to know
    Stephen Supple, Shahjehan Ahmad, Santhosh Gaddikeri, Miral D. Jhaveri
    The British Journal of Radiology.2022;[Epub]     CrossRef
  • Spinal metastases 2021: a review of the current state of the art and future directions
    Daniel M. Sciubba, Zach Pennington, Matthew W. Colman, C. Rory Goodwin, Ilya Laufer, Joshua C. Patt, Kristin J. Redmond, Philip Saylor, John H. Shin, Joseph H. Schwab, Andrew J. Schoenfeld
    The Spine Journal.2021; 21(9): 1414.     CrossRef
  • An updated algorithm for the treatment of spinal metastasis
    Kawngwoo Park, Seong Son, Sang Gu Lee, En Kyung Cho, Hee Kyung Ahn, In Keun Park, Sun Jin Sym, Young Saing Kim
    Journal of the Korean Society of Stereotactic and Functional Neurosurgery.2021; 17(2): 70.     CrossRef
  • Separation surgery for metastatic epidural spinal cord compression: A qualitative review
    Giuseppe Di Perna, Fabio Cofano, Cristina Mantovani, Serena Badellino, Nicola Marengo, Marco Ajello, Ludovico Maria Comite, Giuseppe Palmieri, Fulvio Tartara, Francesco Zenga, Umberto Ricardi, Diego Garbossa
    Journal of Bone Oncology.2020; 25: 100320.     CrossRef
  • Multidisciplinary management of metastatic spine disease: initial symptom-directed management
    Jeremy M Steinberger, Frank Yuk, Amish H Doshi, Sheryl Green, Isabelle M Germano
    Neuro-Oncology Practice.2020; 7(Supplement): i33.     CrossRef
  • 9,789 View
  • 232 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
Nomogram Development and External Validation for Predicting the Risk of Lymph Node Metastasis in T1 Colorectal Cancer
Jung Ryul Oh, Boram Park, Seongdae Lee, Kyung Su Han, Eui-Gon Youk, Doo-Han Lee, Do-Sun Kim, Doo-Seok Lee, Chang Won Hong, Byung Chang Kim, Bun Kim, Min Jung Kim, Sung Chan Park, Dae Kyung Sohn, Hee Jin Chang, Jae Hwan Oh
Cancer Res Treat. 2019;51(4):1275-1284.   Published online January 17, 2019
DOI: https://doi.org/10.4143/crt.2018.569
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Predicting lymph node metastasis (LNM) risk is crucial in determining further treatment strategies following endoscopic resection of T1 colorectal cancer (CRC). This study aimed to establish a new prediction model for the risk of LNM in T1 CRC patients.
Materials and Methods
The development set included 833 patients with T1 CRC who had undergone endoscopic (n=154) or surgical (n=679) resection at the National Cancer Center. The validation set included 722 T1 CRC patients who had undergone endoscopic (n=249) or surgical (n=473) resection at Daehang Hospital. A logistic regression model was used to construct the prediction model. To assess the performance of prediction model, discrimination was evaluated using the receiver operating characteristic (ROC) curves with area under the ROC curve (AUC), and calibration was assessed using the Hosmer-Lemeshow (HL) goodness-of-fit test.
Results
Five independent risk factors were determined in the multivariable model, including vascular invasion, high-grade histology, submucosal invasion, budding, and background adenoma. In final prediction model, the performance of the model was good that the AUC was 0.812 (95% confidence interval [CI], 0.770 to 0.855) and the HL chi-squared test statistic was 1.266 (p=0.737). In external validation, the performance was still good that the AUC was 0.771 (95% CI, 0.708 to 0.834) and the p-value of the HL chi-squared test was 0.040. We constructed the nomogram with the final prediction model.
Conclusion
We presented an externally validated new prediction model for LNM risk in T1 CRC patients, guiding decision making in determining whether additional surgery is required after endoscopic resection of T1 CRC.

Citations

Citations to this article as recorded by  
  • Risk stratification scores for lymph node metastases in T1 colorectal cancer—A systematic review
    Rakesh Quinn, Giuleta Jamsari, Ewan MacDermid
    Colorectal Disease.2025;[Epub]     CrossRef
  • The critical role of tumor size in predicting lymph node metastasis in early-stage colorectal cancer
    Attila Ulkucu, Metincan Erkaya, Ekin Inal, Emre Gorgun
    The American Journal of Surgery.2025; 241: 116152.     CrossRef
  • Risk assessment in pT1 colorectal cancer
    Emma Jane Norton, Adrian C Bateman
    Journal of Clinical Pathology.2024; 77(4): 225.     CrossRef
  • Curative criteria for endoscopic treatment of colorectal cancer
    Lucille Quénéhervé, Mathieu Pioche, Jérémie Jacques
    Best Practice & Research Clinical Gastroenterology.2024; 68: 101883.     CrossRef
  • Commentary: An artificial intelligence prediction model outperforms conventional guidelines in predicting lymph node metastasis of T1 colorectal cancer
    Katsuro Ichimasa, Shin-ei Kudo, Khay Guan Yeoh
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Management after non-curative endoscopic resection of T1 rectal cancer
    Hao Dang, Daan A. Verhoeven, Jurjen J. Boonstra, Monique E. van Leerdam
    Best Practice & Research Clinical Gastroenterology.2024; 68: 101895.     CrossRef
  • A clinical-radiomics nomogram based on spectral CT multi-parameter images for preoperative prediction of lymph node metastasis in colorectal cancer
    Qian Li, Rui Hong, Ping Zhang, Liting Hou, Hailun Bao, Lin Bai, Jian Zhao
    Clinical & Experimental Metastasis.2024; 41(5): 639.     CrossRef
  • A new clinical model for predicting lymph node metastasis in T1 colorectal cancer
    Kai Wang, Hui He, Yanyun Lin, Yanhong Zhang, Junguo Chen, Jiancong Hu, Xiaosheng He
    International Journal of Colorectal Disease.2024;[Epub]     CrossRef
  • Predictors of early colorectal cancer metastasis to lymph nodes: providing rationale for therapy decisions
    Xu Song, Jun Li, Jiang Zhu, Yun-Fei Kong, Yu-Hang Zhou, Zi-Kun Wang, Jin Zhang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Approaches and considerations in the endoscopic treatment of T1 colorectal cancer
    Yunho Jung
    The Korean Journal of Internal Medicine.2024; 39(4): 563.     CrossRef
  • A Nomogram for Predicting Unplanned Intraoperative Hypothermia in Patients With Colorectal Cancer Undergoing Laparoscopic Colorectal Procedures
    Lupei Yan, Jingxing Tan, Hao Chen, Han Xiao, Yi Zhang, Qin Yao, Yuerong Li
    AORN Journal.2023;[Epub]     CrossRef
  • A proposal for grading the risk of lymph node metastasis after endoscopic resection of T1 colorectal cancer
    Zhenghua Piao, Rong Ge, Chunnian Wang
    International Journal of Colorectal Disease.2023;[Epub]     CrossRef
  • Nomogram as a novel predictive tool for lymph node metastasis in T1 colorectal cancer treated with endoscopic resection: a nationwide, multicenter study
    Yoshiki Kajiwara, Shiro Oka, Shinji Tanaka, Takahiro Nakamura, Shoichi Saito, Yosuke Fukunaga, Manabu Takamatsu, Hiroshi Kawachi, Kinichi Hotta, Hiroaki Ikematsu, Motohiro Kojima, Yutaka Saito, Masayoshi Yamada, Yukihide Kanemitsu, Shigeki Sekine, Shinji
    Gastrointestinal Endoscopy.2023; 97(6): 1119.     CrossRef
  • CT morphological features for predicting the risk of lymph node metastasis in T1 colorectal cancer
    Suyun Li, Zhenhui Li, Li Wang, Mimi Wu, Xiaobo Chen, Chutong He, Yao Xu, Mengyi Dong, Yanting Liang, Xin Chen, Zaiyi Liu
    European Radiology.2023; 33(10): 6861.     CrossRef
  • Prediction model for lymph node metastasis in superficial colorectal cancer: a better choice than computed tomography
    Chao-Tao Tang, Jun Li, Peng Wang, You-Xiang Chen, Chun-Yan Zeng
    Surgical Endoscopy.2023; 37(10): 7444.     CrossRef
  • Lymph Node Molecular Analysis with OSNA Enables the Identification of pT1 CRC Patients at Risk of Recurrence: A Multicentre Study
    Karmele Saez de Gordoa, Maria Teresa Rodrigo-Calvo, Ivan Archilla, Sandra Lopez-Prades, Alba Diaz, Jordi Tarragona, Isidro Machado, Juan Ruiz Martín, Diana Zaffalon, Maria Daca-Alvarez, Maria Pellisé, Jordi Camps, Miriam Cuatrecasas
    Cancers.2023; 15(22): 5481.     CrossRef
  • Prediction of disease recurrence or residual disease after primary endoscopic resection of pT1 colorectal cancer—results from a large nationwide Danish study
    Ilze Ose, Katarina Levic, Lau Caspar Thygesen, Orhan Bulut, Thue Bisgaard, Ismail Gögenur, Tine Plato Kuhlmann
    International Journal of Colorectal Disease.2023;[Epub]     CrossRef
  • Endoscopic resection alone as a potential treatment method for low-risk deep invasive T1 colorectal cancer
    Yuta Kouyama, Shin-ei Kudo, Katsuro Ichimasa, Shingo Matsudaira, Yushi Ogawa, Kenichi Mochizuki, Yuki Takashina, Yuta Sato, Tatsuya Sakurai, Yasuharu Maeda, Hiroki Nakamura, Masashi Misawa, Yuichi Mori, Toyoki Kudo, Takemasa Hayashi, Kunihiko Wakamura, Te
    iGIE.2023; 2(4): 503.     CrossRef
  • A Retrospective Multicenter Study of Risk Factors, Stratification, and Prognosis of Lymph Node Metastasis in T1 and T2 Colorectal Cancer
    Eui Myung Kim, Il Tae Son, Byung Chun Kim, Jun Ho Park, Byung Mo Kang, Jong Wan Kim
    Journal of Clinical Medicine.2023; 12(24): 7744.     CrossRef
  • Risk and Time Pattern of Recurrences After Local Endoscopic Resection of T1 Colorectal Cancer: A Meta-analysis
    Hao Dang, Nik Dekkers, Saskia le Cessie, Jeanin E. van Hooft, Monique E. van Leerdam, Philip P. Oldenburg, Louis Flothuis, Jan W. Schoones, Alexandra M.J. Langers, James C.H. Hardwick, Jolein van der Kraan, Jurjen J. Boonstra
    Clinical Gastroenterology and Hepatology.2022; 20(2): e298.     CrossRef
  • Lymphatic Node Metastasis Risk Scoring System: A Novel Instrument for Predicting Lymph Node Metastasis After Thymic Epithelial Tumor Resection
    Xinxin Cheng, Yaxin Lu, Sai Chen, Weilin Yang, Bo Xu, Jianyong Zou, Zhenguang Chen
    Annals of Surgical Oncology.2022; 29(1): 598.     CrossRef
  • Current problems and perspectives of pathological risk factors for lymph node metastasis in T1 colorectal cancer: Systematic review
    Katsuro Ichimasa, Shin‐ei Kudo, Hideyuki Miyachi, Yuta Kouyama, Kenichi Mochizuki, Yuki Takashina, Yasuharu Maeda, Yuichi Mori, Toyoki Kudo, Yuki Miyata, Yoshika Akimoto, Yuki Kataoka, Takafumi Kubota, Tetsuo Nemoto, Fumio Ishida, Masashi Misawa
    Digestive Endoscopy.2022; 34(5): 901.     CrossRef
  • Tumor Location as a Prognostic Factor in T1 Colorectal Cancer
    Katsuro Ichimasa, Shin-ei Kudo, Yuta Kouyama, Kenichi Mochizuki, Yuki Takashina, Masashi Misawa, Yuichi Mori, Takemasa Hayashi, Kunihiko Wakamura, Hideyuki Miyachi
    Journal of the Anus, Rectum and Colon.2022; 6(1): 9.     CrossRef
  • Identification of Predictive Factors for Lymph Node Metastasis in pT1 Stage Colorectal Cancer Patients: A Retrospective Analysis Based on the Population Database
    Jiawei Song, Huanhuan Yin, Yong Zhu, Shengqi Fei
    Pathology and Oncology Research.2022;[Epub]     CrossRef
  • Establishment of a Dynamic Nomogram for Predicting the Risk of Lymph Node Metastasis in T1 Stage Colorectal Cancer
    Zitao Liu, Chao Huang, Huakai Tian, Yu Liu, Yongshan Huang, Zhengming Zhu
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Deep Submucosal Invasion Is Not an Independent Risk Factor for Lymph Node Metastasis in T1 Colorectal Cancer: A Meta-Analysis
    Liselotte W. Zwager, Barbara A.J. Bastiaansen, Nahid S.M. Montazeri, Roel Hompes, Valeria Barresi, Katsuro Ichimasa, Hiroshi Kawachi, Isidro Machado, Tadahiko Masaki, Weiqi Sheng, Shinji Tanaka, Kazutomo Togashi, Chihiro Yasue, Paul Fockens, Leon M.G. Moo
    Gastroenterology.2022; 163(1): 174.     CrossRef
  • Composite scoring system and optimal tumor budding cut-off number for estimating lymph node metastasis in submucosal colorectal cancer
    Jeong-ki Kim, Ye-Young Rhee, Jeong Mo Bae, Jung Ho Kim, Seong-Joon Koh, Hyun Jung Lee, Jong Pil Im, Min Jung Kim, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park, Ji Won Park, Gyeong Hoon Kang
    BMC Cancer.2022;[Epub]     CrossRef
  • Lymph node metastasis in T1 colorectal cancer with the only high-risk histology of submucosal invasion depth ≥ 1000 μm
    Yusuke Yamaoka, Akio Shiomi, Hiroyasu Kagawa, Hitoshi Hino, Shoichi Manabe, Kai Chen, Kenji Nanishi, Akifumi Notsu
    International Journal of Colorectal Disease.2022; 37(11): 2387.     CrossRef
  • Subpopulation analysis of survival in high-risk T1 colorectal cancer: surgery versus endoscopic resection only
    Ryun Kyong Ha, Boram Park, Kyung Su Han, Dae Kyung Sohn, Chang Won Hong, Byung Chang Kim, Bun Kim, Sung Chan Park, Hee Jin Chang, Jae Hwan Oh
    Gastrointestinal Endoscopy.2022; 96(6): 1036.     CrossRef
  • Preoperative prediction of lymph node status in patients with colorectal cancer. Developing a predictive model using machine learning
    Morten Hartwig, Karoline Bendix Bräuner, Rasmus Vogelsang, Ismail Gögenur
    International Journal of Colorectal Disease.2022; 37(12): 2517.     CrossRef
  • Preoperative Predictors of Lymph Node Metastasis in Colon Cancer
    Yansong Xu, Yi Chen, Chenyan Long, Huage Zhong, Fangfang Liang, Ling-xu Huang, Chuanyi Wei, Shaolong Lu, Weizhong Tang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • LASSO-Based Machine Learning Algorithm for Prediction of Lymph Node Metastasis in T1 Colorectal Cancer
    Jeonghyun Kang, Yoon Jung Choi, Im-kyung Kim, Hye Sun Lee, Hogeun Kim, Seung Hyuk Baik, Nam Kyu Kim, Kang Young Lee
    Cancer Research and Treatment.2021; 53(3): 773.     CrossRef
  • Risk Stratification of T1 Colorectal Cancer Metastasis to Lymph Nodes: Current Status and Perspective
    Katsuro Ichimasa, Shin-ei Kudo, Hideyuki Miyachi, Yuta Kouyama, Masashi Misawa, Yuichi Mori
    Gut and Liver.2021; 15(6): 818.     CrossRef
  • Supervised Learning Based Systemic Inflammatory Markers Enable Accurate Additional Surgery for pT1NxM0 Colorectal Cancer: A Comparative Analysis of Two Practical Prediction Models for Lymph Node Metastasis
    Jinlian Jin, Haiyan Zhou, Shulin Sun, Zhe Tian, Haibing Ren, Jinwu Feng
    Cancer Management and Research.2021; Volume 13: 8967.     CrossRef
  • Risk factors and predictors of lymph nodes metastasis and distant metastasis in newly diagnosed T1 colorectal cancer
    Kaibo Guo, Yuqian Feng, Li Yuan, Harpreet S. Wasan, Leitao Sun, Minhe Shen, Shanming Ruan
    Cancer Medicine.2020; 9(14): 5095.     CrossRef
  • Development and external validation of a predictive scoring system associated with metastasis of T1‐2 colorectal tumors to lymph nodes
    Shaobo Mo, Zheng Zhou, Weixing Dai, Wenqiang Xiang, Lingyu Han, Long Zhang, Renjie Wang, Sanjun Cai, Qingguo Li, Guoxiang Cai
    Clinical and Translational Medicine.2020; 10(1): 275.     CrossRef
  • Inverse Association of Age with Risk of Lymph Node Metastasis in Superficial Colorectal Cancer: A Large Population-Based Study
    Qing-Wei Zhang, Long-Ci Sun, Chao-Tao Tang, Qian Liang, Yang-Yang Zhou, Hui-Min Chen, Yun-Jie Gao, Zhi-Zheng Ge
    The Oncologist.2020; 25(6): e920.     CrossRef
  • T1 colorectal cancers: The impact of screening programs on a curable disease
    Adriana Vaz Safatle-Ribeiro
    Digestive and Liver Disease.2020; 52(8): 918.     CrossRef
  • Risk factors and risk prediction models for colorectal cancer metastasis and recurrence: an umbrella review of systematic reviews and meta-analyses of observational studies
    Wei Xu, Yazhou He, Yuming Wang, Xue Li, Jane Young, John P. A. Ioannidis, Malcolm G. Dunlop, Evropi Theodoratou
    BMC Medicine.2020;[Epub]     CrossRef
  • 10,103 View
  • 378 Download
  • 39 Web of Science
  • 39 Crossref
Close layer
Verification of Low Risk for Perihippocampal Recurrence in Patients with Brain Metastases Who Received Whole-Brain Radiotherapy with Hippocampal Avoidance
Youngkyong Kim, Sung Hwan Kim, Jong Hoon Lee, Dae Gyu Kang
Cancer Res Treat. 2019;51(2):568-575.   Published online July 16, 2018
DOI: https://doi.org/10.4143/crt.2018.206
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to analyze the patterns of failure and survival outcome in patients with brain metastases who received whole-brain radiotherapy (WBRT) with hippocampal avoidance (HA) using simultaneous integrated boost (SIB) on metastatic brain tumors.
Materials and Methods
We retrospectively reviewed 42 patients treated with HA-WBRT for brain metastases. A total of 25 Gy for whole brain and 35-55 Gy for gross tumors were delivered with 10 fractionations. Local tumor and intracranial progression were defined as a recurrence or tumor progression in SIB field and any recurrence or tumor progression within whole brain, respectively. Progression in HA zone was defined as the recurrence within the area expanded 5 mm from HA zone.
Results
Median follow-up duration was 10.0 months (range, 4.1 to 56.4 months). Intracranial progression was observed in 13 patients (31.0%) and the median duration from the start of HA-WBRT to progression was 10.6 months (range, 0.9 to 33.0 months). Local tumor progression and new metastasis outside SIB field occurred in 10 patients (23.8%) and nine patients (21.4%), respectively. There was no isolated hippocampal metastasis, except only one patient (2.4%) with multiple metastases inside and outside HA zone simultaneously. Median survival time and intracranial progression-free survival rate at 1 year were 19.4 months (95% confidence interval [CI], 9.6 to 29.2) and 71.5%, respectively, and those for overall survival were 26.5 months (95% CI, 15.4 to 37.5) and 67.9%, respectively.
Conclusion
HA-WBRT was associated with low risk of new metastasis in HA region in the patients with brain metastases. These findings would serve as useful guidance on applying HA-WBRT in clinical practice.

Citations

Citations to this article as recorded by  
  • Incidence of hippocampal and perihippocampal brain metastases and impact on hippocampal-avoiding radiotherapy: A systematic review and meta-analysis
    Shari Wiegreffe, Gustavo Renato Sarria, Julian Philipp Layer, Egon Dejonckheere, Younèss Nour, Frederic Carsten Schmeel, Frank Anton Giordano, Leonard Christopher Schmeel, Ilinca Popp, Anca-Ligia Grosu, Eleni Gkika, Cas Stefaan Dejonckheere
    Radiotherapy and Oncology.2024; 197: 110331.     CrossRef
  • Recommendation for the contouring of limbic system in patients receiving radiation treatment: A pictorial review for the everyday practice and education
    Claudia Sorce, Agnieszka Chalaszczyk, Francesca Rossi, Letizia Ferella, Gianmarco Grimaldi, Alessandra Splendiani, Domenico Genovesi, Francesco Marampon, Ester Orlandi, Alberto Iannalfi, Carlo Masciocchi, Giovanni Luca Gravina
    Critical Reviews in Oncology/Hematology.2021; 159: 103229.     CrossRef
  • Dose-Effects Models for Space Radiobiology: An Overview on Dose-Effect Relationships
    Lidia Strigari, Silvia Strolin, Alessio Giuseppe Morganti, Alessandro Bartoloni
    Frontiers in Public Health.2021;[Epub]     CrossRef
  • Leukoencephalopathy after prophylactic whole-brain irradiation with or without hippocampal sparing: a longitudinal magnetic resonance imaging analysis
    Michael Mayinger, Johannes Kraft, Niklas Lohaus, Michael Weller, Daniel Schanne, Jana Heitmann, Jonas Willmann, Lotte Wilke, Jérôme Krayenbuehl, Stephanie Tanadini-Lang, Matthias Guckenberger, Nicolaus Andratschke
    European Journal of Cancer.2020; 124: 194.     CrossRef
  • Initial experiences with hippocampus-sparing whole-brain radiotherapy for lung cancer patients
    M. Nielsen, C. Kristiansen, T. Schytte, O. Hansen
    Acta Oncologica.2019; 58(10): 1540.     CrossRef
  • 6,646 View
  • 157 Download
  • 6 Web of Science
  • 5 Crossref
Close layer
A Novel Prognostic Nomogram for Predicting Risks of Distant Failure in Patients with Invasive Breast Cancer Following Postoperative Adjuvant Radiotherapy
Yu Jin Lim, Sea-Won Lee, Noorie Choi, Jeanny Kwon, Keun-Yong Eom, Eunyoung Kang, Eun-Kyu Kim, Jee Hyun Kim, Yu Jung Kim, Se Hyun Kim, So Yeon Park, In Ah Kim
Cancer Res Treat. 2018;50(4):1140-1148.   Published online December 7, 2017
DOI: https://doi.org/10.4143/crt.2017.508
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to identify predictors for distant metastatic behavior and build a related prognostic nomogram in breast cancer.
Materials and Methods
A total of 1,181 patients with non-metastatic breast cancer between 2003 and 2011 were analyzed. To predict the probability of distant metastasis, a nomogram was constructed based on prognostic factors identified using a Cox proportional hazards model.
Results
The 7-year overall survival and 5-year post-progression survival of locoregional versus distant recurrence groups were 67.6% versus 39.1% (p=0.027) and 54.2% versus 33.5% (p=0.043), respectively. Patients who developed distant metastasis showed early and late mortality risk peaks within 3 and after 5 years of follow-up, respectively, but a broad and low risk increment was observed in other patients with locoregional relapse. In multivariate analysis of distant metastasis-free interval, age (≥ 45 years vs. < 45 years), molecular subtypes (luminal A vs. luminal B, human epidermal growth receptor 2, and triple negative), T category (T1 vs. T2-3 and T4), and N category (N0 vs. N1 and N2-3) were independently associated (p < 0.05 for all). Regarding the significant factors, a well-validated nomogram was established (concordance index, 0.812). The risk score level of patients with initial brain failure was higher than those of non-brain sites (p=0.029).
Conclusion
The nomogram could be useful for predicting the individual probability of distant recurrence in breast cancer. In high-risk patients based on the risk scores, more aggressive systemic therapy and closer surveillance for metastatic failure should be considered.

Citations

Citations to this article as recorded by  
  • Predicting Patterns of Distant Metastasis in Breast Cancer Patients following Local Regional Therapy Using Machine Learning
    Audrey Shiner, Alex Kiss, Khadijeh Saednia, Katarzyna J. Jerzak, Sonal Gandhi, Fang-I Lu, Urban Emmenegger, Lauren Fleshner, Andrew Lagree, Marie Angeli Alera, Mateusz Bielecki, Ethan Law, Brianna Law, Dylan Kam, Jonathan Klein, Christopher J. Pinard, Ale
    Genes.2023; 14(9): 1768.     CrossRef
  • Nomograms for Predicting Specific Distant Metastatic Sites and Overall Survival of Breast Invasive Ductal Carcinoma Patients After Surgery: A Large Population-Based Study
    Yuqian Feng, Yiting Zhang, Yuying Xiang, Kaibo Guo, Huimin Jin, Shanming Ruan, Zhuoya Guan
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer
    Jing Yang, Shu-Nan Qi, Hui Fang, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Wei-Hu Wang, Yong Yang, Yu Tang, Hua Ren, Bo Chen, Ning-Ning Lu, Yuan Tang, Ning Li, Hao Jing, Shu-Lian Wang, Ye-Xiong Li
    The Breast.2021; 58: 72.     CrossRef
  • Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer
    Koji Takada, Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Rika Kouhashi, Akimichi Yabumoto, Sae Ishihara, Tamami Morisaki, Masatsune Shibutani, Hiroaki Tanaka, Kosei Hirakawa, Masaichi Ohira
    BMC Women's Health.2021;[Epub]     CrossRef
  • Nomogram for the personalisation of radiotherapy treatments in breast cancer patients
    Inmaculada Beato Tortajada, Carlos Ferrer Albiach, Virginia Morillo Macias
    The Breast.2021; 60: 255.     CrossRef
  • Prognostic Factors and Nomograms to Predict Overall and Cancer-Specific Survival for Children with Wilms’ Tumor
    Fucai Tang, Hanbin Zhang, Zechao Lu, Jiamin Wang, Chengwu He, Zhaohui He
    Disease Markers.2019; 2019: 1.     CrossRef
  • Score for the Survival Probability in Metastasis Breast Cancer: A Nomogram-Based Risk Assessment Model
    Zhenchong Xiong, Guangzheng Deng, Xinjian Huang, Xing Li, Xinhua Xie, Jin Wang, Zeyu Shuang, Xi Wang
    Cancer Research and Treatment.2018; 50(4): 1260.     CrossRef
  • 9,182 View
  • 233 Download
  • 11 Web of Science
  • 7 Crossref
Close layer
Prognostic Factors and Decision Tree for Long-Term Survival in Metastatic Uveal Melanoma
Daniel Lorenzo, María Ochoa, Josep Maria Piulats, Cristina Gutiérrez, Luis Arias, Jaume Català, María Grau, Judith Peñafiel, Estefanía Cobos, Pere Garcia-Bru, Marcos Javier Rubio, Noel Padrón-Pérez, Bruno Dias, Joan Pera, Josep Maria Caminal
Cancer Res Treat. 2018;50(4):1130-1139.   Published online December 4, 2017
DOI: https://doi.org/10.4143/crt.2017.171
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to demonstrate the existence of a bimodal survival pattern in metastatic uveal melanoma. Secondary aims were to identify the characteristics and prognostic factors associated with long-term survival and to develop a clinical decision tree.
Materials and Methods
The medical records of 99 metastatic uveal melanoma patients were retrospectively reviewed. Patients were classified as either short (≤ 12 months) or long-term survivors (> 12 months) based on a graphical interpretation of the survival curve after diagnosis of the first metastatic lesion. Ophthalmic and oncological characteristicswere assessed in both groups.
Results
Of the 99 patients, 62 (62.6%) were classified as short-term survivors, and 37 (37.4%) as long-term survivors. The multivariate analysis identified the following predictors of long-term survival: age ≤ 65 years (p=0.012) and unaltered serum lactate dehydrogenase levels (p=0.018); additionally, the size (smaller vs. larger) of the largest liver metastasis showed a trend towards significance (p=0.063). Based on the variables significantly associated with long-term survival, we developed a decision tree to facilitate clinical decision-making.
Conclusion
The findings of this study demonstrate the existence of a bimodal survival pattern in patients with metastatic uveal melanoma. The presence of certain clinical characteristics at diagnosis of distant disease is associated with long-term survival. A decision tree was developed to facilitate clinical decision-making and to counsel patients about the expected course of disease.

Citations

Citations to this article as recorded by  
  • A Systematic Review of Prognostic Factors in Patients with Cancer Receiving Palliative Radiotherapy: Evidence-Based Recommendations
    Alexander Tam, Emanuela Scarpi, Marco Cesare Maltoni, Romina Rossi, Alysa Fairchild, Kristopher Dennis, Marcus Vaska, Marc Kerba
    Cancers.2024; 16(9): 1654.     CrossRef
  • Comparative assessment of the capability of machine learning-based radiomic models for predicting omental metastasis in locally advanced gastric cancer
    Ahao Wu, Lianghua Luo, Qingwen Zeng, Changlei Wu, Xufeng Shu, Pang Huang, Zhonghao Wang, Tengcheng Hu, Zongfeng Feng, Yi Tu, Yanyan Zhu, Yi Cao, Zhengrong Li
    Scientific Reports.2024;[Epub]     CrossRef
  • Impact of Metastatic Pattern on Survival in Patients with Posterior Uveal Melanoma: A Retrospective Cohort Study
    Tine G. Hindso, Peter S. Jensen, Mette B. Sjøl, Kristoffer Nissen, Camilla W. Bjerrum, Eric von Benzon, Carsten Faber, Steen F. Urbak, Marco Donia, Inge M. Svane, Eva Ellebaek, Steffen Heegaard, Karine Madsen, Jens F. Kiilgaard
    Cancers.2024; 16(19): 3346.     CrossRef
  • Orthotopic murine xenograft model of uveal melanoma with spontaneous liver metastasis
    Raquel Ramos, Eduard Cabré, Antònia Vinyals, Daniel Lorenzo, Josep R. Ferreres, Mar Varela, Montse Gomá, Maria José Paules, Cristina Gutierrez, Josep M. Piulats, Àngels Fabra, José M. Caminal
    Melanoma Research.2023; 33(1): 1.     CrossRef
  • Determinants of Long-Term Survival in Metastatic Choroidal and Ciliary Body Melanoma
    Elina S. Rantala, Raffaele Parrozzani, Micaela M. Hernberg, Vanna Chiarion-Sileni, Tero T. Kivelä, Edoardo Midena
    American Journal of Ophthalmology.2023; 246: 258.     CrossRef
  • Development and validation of machine learning models for predicting prognosis and guiding individualized postoperative chemotherapy: A real-world study of distal cholangiocarcinoma
    Di Wang, Bing Pan, Jin-Can Huang, Qing Chen, Song-Ping Cui, Ren Lang, Shao-Cheng Lyu
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Applications of Artificial Intelligence in Ocular Oncology
    Bhavna Chawla, Kusumitha B. Ganesh
    Advances in Ophthalmology and Optometry.2023; 8(1): 111.     CrossRef
  • Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis
    Luis P. del Carpio, María Asunción Algarra, Aida Sabaté‐Llobera, Alejo Rodriguez‐Vida, Susana Rossi‐Seoane, Sandra Ruiz, David Leiva, Emilio Ramos, Laura Lladò, Daniel Lorenzo, Cristina Gutierrez, Montserrat Cortes‐Romera, Josep M. Caminal, Josep M. Piula
    Cancer Medicine.2023; 12(13): 14062.     CrossRef
  • Patients presenting with metastases: stage IV uveal melanoma, an international study
    Gaurav Garg, Paul T Finger, Tero T Kivelä, E Rand Simpson, Brenda L Gallie, Svetlana Saakyan, Anush G Amiryan, Vladimir Valskiy, Kimberly J Chin, Ekaterina Semenova, Stefan Seregard, Maria Filì, Matthew Wilson, Barrett Haik, Josep Maria Caminal, Jaume Cat
    British Journal of Ophthalmology.2022; 106(4): 510.     CrossRef
  • Metastatic uveal melanoma: The final frontier
    Elina S. Rantala, Micaela M. Hernberg, Sophie Piperno-Neumann, Hans E. Grossniklaus, Tero T. Kivelä
    Progress in Retinal and Eye Research.2022; 90: 101041.     CrossRef
  • The Application of Artificial Intelligence in the Analysis of Biomarkers for Diagnosis and Management of Uveitis and Uveal Melanoma: A Systematic Review
    Arshpreet Bassi, Saffire H Krance, Aidan Pucchio, Daiana R Pur, Rafael N Miranda, Tina Felfeli
    Clinical Ophthalmology.2022; Volume 16: 2895.     CrossRef
  • A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol
    Anukriti Sharma, Ken B. Johnson, Bihua Bie, Emily E. Rhoades, Alper Sen, Yuri Kida, Jennifer Hockings, Alycia Gatta, Jacqueline Davenport, Connie Arcangelini, Jennifer Ritzu, Jennifer DeVecchio, Ron Hughen, Mei Wei, G. Thomas Budd, N. Lynn Henry, Charis E
    Technology in Cancer Research & Treatment.2022;[Epub]     CrossRef
  • Nomogram, Decision Tree and Deep Learning Models to Predict Lymph Node Metastasis of Patients with Early Gastric Cancer: A Multi-Cohort Study
    Lulu Zhao, Weili Han, Penghui Niu, Yuanyuan Lu, Fan Zhang, Fuzhi Jiao, Xiadong Zhou, Wanqing Wang, Xiaoyi Luan, Mingyan He, Quanlin Guan, Yu-min Li, Yongzhan Nie, Kaichun Wu, Yingtai Chen
    SSRN Electronic Journal.2022;[Epub]     CrossRef
  • ALKBH5-mediated m6A demethylation of FOXM1 mRNA promotes progression of uveal melanoma
    Lili Hao, Jiayang Yin, Hong Yang, Chaoxuan Li, Linxin Zhu, Lian Liu, Jingxiang Zhong
    Aging.2021; 13(3): 4045.     CrossRef
  • Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma
    Elina S. Rantala, Tero T. Kivelä, Micaela M. Hernberg
    Melanoma Research.2021; 31(3): 224.     CrossRef
  • Classification trees for predicting obesity in school-aged children
    E.V. Anufrieva, V.N. Shershnev, O.P. Kovtun
    Profilakticheskaya meditsina.2021; 24(7): 30.     CrossRef
  • Choroidal Melanoma with Ultrasound-Guided Episcleral Brachytherapy: Long-Term Results and Risk of Metastasis
    Beatriz Quiles, Jorge Mataix, José Luis Guinot, Isabel Wang, Victor De los Dolores, Marina Peña, Alonso La Rosa, Maribel Tortajada, Miguel Santos, Leoncio Arribas
    Ocular Oncology and Pathology.2021; 7(4): 280.     CrossRef
  • Development of a Prognostic Nomogram for Liver Metastasis of Uveal Melanoma Patients Selected by Liver MRI
    Pascale Mariani, Sylvain Dureau, Alexia Savignoni, Livia Lumbroso-Le Rouic, Christine Levy-Gabriel, Sophie Piperno-Neumann, Manuel J. Rodrigues, Laurence Desjardins, Nathalie Cassoux, Vincent Servois
    Cancers.2019; 11(6): 863.     CrossRef
  • Iterative treatment with surgery and radiofrequency ablation of uveal melanoma liver metastasis: Retrospective analysis of a series of very long-term survivors
    Vincent Servois, Toufik Bouhadiba, Sylvain Dureau, Carla Da Costa, Mohamed Maher Almubarak, Romain Foucher, Alexia Savignoni, Nathalie Cassoux, Gaelle Pierron, Pascale Mariani
    European Journal of Surgical Oncology.2019; 45(9): 1717.     CrossRef
  • 9,175 View
  • 274 Download
  • 21 Web of Science
  • 19 Crossref
Close layer
The Clinical Significance of Occult Gastrointestinal Primary Tumours in Metastatic Cancer: A Population Retrospective Cohort Study
Malek B. Hannouf, Eric Winquist, Salaheddin M. Mahmud, Muriel Brackstone, Sisira Sarma, George Rodrigues, Peter K. Rogan, Jeffrey S. Hoch, Gregory S. Zaric
Cancer Res Treat. 2018;50(1):183-194.   Published online March 21, 2017
DOI: https://doi.org/10.4143/crt.2016.532
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to estimate the incidence of occult gastrointestinal (GI) primary tumours in patients with metastatic cancer of uncertain primary origin and evaluate their influence on treatments and overall survival (OS).
Materials and Methods
We used population heath data from Manitoba, Canada to identify all patients initially diagnosed with metastatic cancer between 2002 and 2011. We defined patients to have “occult” primary tumour if the primary was found at least 6 months after initial diagnosis. Otherwise, we considered primary tumours as “obvious.” We used propensity-score methods to match each patient with occult GI tumour to four patients with obvious GI tumour on all known clinicopathologic features. We compared treatments and 2-year survival data between the two patient groups and assessed treatment effect on OS using Cox regression adjustment.
Results
Eighty-three patients had occult GI primary tumours, accounting for 17.6% of men and 14% of women with metastatic cancer of uncertain primary. A 1:4 matching created a matched group of 332 patients with obvious GI primary tumour. Occult cases compared to the matched group were less likely to receive surgical interventions and targeted biological therapy, and more likely to receive cytotoxic empiric chemotherapeutic agents. Having an occult GI tumour was associated with reduced OS and appeared to be a nonsignificant independent predictor of OS when adjusting for treatment differences.
Conclusion
GI tumours are the most common occult primary tumours in men and the second most common in women. Patients with occult GI primary tumours are potentially being undertreated with available GI site-specific and targeted therapies.

Citations

Citations to this article as recorded by  
  • Relationship between metastasis and second primary cancers in women with breast cancer
    Chaofan Li, Mengjie Liu, Jia Li, Xixi Zhao, Yusheng Wang, Xi Chen, Weiwei Wang, Shiyu Sun, Cong Feng, Yifan Cai, Fei Wu, Chong Du, Yinbin Zhang, Shuqun Zhang, Jingkun Qu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study
    Malek B. Hannouf, Eric Winquist, Salaheddin M. Mahmud, Muriel Brackstone, Sisira Sarma, George Rodrigues, Peter K. Rogan, Jeffrey S. Hoch, Gregory S. Zaric
    PharmacoEconomics - Open.2018; 2(3): 255.     CrossRef
  • 9,192 View
  • 140 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Magnetic Resonance Imaging for Colorectal Cancer Metastasis to the Liver: Comparative Effectiveness Research for the Choice of Contrast Agents
Nieun Seo, Mi-Suk Park, Kyunghwa Han, Kyung Ho Lee, Seong Ho Park, Gi Hong Choi, Jin-Young Choi, Yong Eun Chung, Myeong-Jin Kim
Cancer Res Treat. 2018;50(1):60-70.   Published online March 14, 2017
DOI: https://doi.org/10.4143/crt.2016.533
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to compare the diagnostic performance and early recurrence rate between gadoxetic acid–enhanced magnetic resonance imaging (Gd-EOB-MRI) and magnetic resonance imaging (MRI) with extracellular contrast agent (ECA-MRI) for evaluating hepatic lesions in colorectal cancer.
Materials and Methods
Between 2005 and 2010, 418 colorectal cancer patients with both preoperative computed tomography (CT) and liver MRI were retrospectively reviewed. Image analysis was based on initial radiologic reports, and diagnostic performance was assessed based on the area under the receiver operating characteristic curve (AUROC). The early intrahepatic recurrence rate within 6 months was then evaluated.
Results
Overall, 291 and 127 patients underwent Gd-EOB-MRI and ECA-MRI, respectively. The AUROCs were not significantly different between Gd-EOB-MRI (0.990; 95% CI, 0.980 to 0.999) and ECA-MRI (0.985; 95% CI, 0.968 to 1.000; p=0.836). When compared with CT alone, ECA-MRI detected additional 21 lesions in 14 patients (14/127, 11.0%), whereas Gd-EOB-MRI detected 56 lesions in 33 patients (33/291, 11.3%) without a significant difference between two MRI groups (p=0.331). The early recurrence rate in the ECA-MRI (28.6%) was significantly higher than that in the Gd-EOB-MRI (11.6%) for patients who underwent hepatic resection (p=0.031).
Conclusion
Gd-EOB-MRI is potentially better than ECA-MRI for decreasing the early intrahepatic recurrence rate, although the two MRI modalities showed comparable diagnostic performance in colorectal cancer patients.

Citations

Citations to this article as recorded by  
  • Clinical performance of a simulated abbreviated liver magnetic resonance imaging in combination with contrast-enhanced computed tomography for the baseline evaluation of the liver in patients with colorectal cancer
    F. Castagnoli, S.J. Withey, M. Konidari, I. Chau, A. Riddell, J. Shur, C. Messiou, D.M. Koh
    Clinical Radiology.2025; 80: 106743.     CrossRef
  • Collaborative multi-feature extraction and scale-aware semantic information mining for medical image segmentation
    Ruijun Zhang, Zixuan He, Jian Zhu, Xiaochen Yuan, Guoheng Huang, Chi-Man Pun, Jianhong Peng, Junzhong Lin, Jian Zhou
    Physics in Medicine & Biology.2022; 67(20): 205008.     CrossRef
  • Diagnostic Performance of Deep Learning-Based Lesion Detection Algorithm in CT for Detecting Hepatic Metastasis from Colorectal Cancer
    Kiwook Kim, Sungwon Kim, Kyunghwa Han, Heejin Bae, Jaeseung Shin, Joon Seok Lim
    Korean Journal of Radiology.2021; 22(6): 912.     CrossRef
  • Application of intraoperative ultrasound in liver surgery
    Ya-Wei Xu, Hong Fu
    Hepatobiliary & Pancreatic Diseases International.2021; 20(5): 501.     CrossRef
  • Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma
    Hye Jin Kim, Mi-Suk Park, Jin Yong Lee, Kyunghwa Han, Yong Eun Chung, Jin-Young Choi, Myeong-Jin Kim, Chang Moo Kang
    Cancer Research and Treatment.2019; 51(1): 24.     CrossRef
  • Abbreviated Gadoxetic Acid–enhanced MRI with Second-Shot Arterial Phase Imaging for Liver Metastasis Evaluation
    Jeong Woo Kim, Chang Hee Lee, Yang Shin Park, Jongmee Lee, Kyeong Ah Kim
    Radiology: Imaging Cancer.2019; 1(1): e190006.     CrossRef
  • Intraoperative Ultrasound Staging for Colorectal Liver Metastases in the Era of Liver-Specific Magnetic Resonance Imaging: Is It Still Worthwhile?
    Serena Langella, Francesco Ardito, Nadia Russolillo, Elena Panettieri, Serena Perotti, Caterina Mele, Felice Giuliante, Alessandro Ferrero
    Journal of Oncology.2019; 2019: 1.     CrossRef
  • Capabilities of 18F-FDG PET/CT in the differential diagnosis of colorectal liver metastases
    M. S. Tlostanova, A. L. Dolbov, A. A. Stanzhevskii
    Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2019; 24(4): 18.     CrossRef
  • 12,131 View
  • 356 Download
  • 9 Web of Science
  • 8 Crossref
Close layer
Downregulation of HuR Inhibits the Progression of Esophageal Cancer through Interleukin-18
Xiaohui Xu, Cheng Song, Zhihua Chen, Chenxiao Yu, Yi Wang, Yiting Tang, Judong Luo
Cancer Res Treat. 2018;50(1):71-87.   Published online February 24, 2017
DOI: https://doi.org/10.4143/crt.2017.013
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the effect of human antigen R (HuR) downregulation and the potential target genes of HuR on the progression of esophageal squamous cell carcinoma (ESCC).
Materials and Methods
In this study, a proteomics assay was used to detect the expression of proteins after HuR downregulation, and a luciferase assay was used to detect the potential presence of a HuR binding site on the 3’-untranslated region (3'-UTR) of interleukin 18 (IL-18). In addition, colony formation assay, MTT, EdU incorporation assay, Western blot, flow cytometry, immunohistochemistry, transwell invasion assay, and wound healing assay were used.
Results
In the present study, we found that the expression of both HuR protein and mRNA levels were higher in tumor tissues than in the adjacent tissues. HuR downregulation significantly suppressed cell proliferation. In addition, the metastasis of esophageal cancer cells was inhibited, while the expression of E-cadherin was increased and the expression of matrix metalloproteinase (MMP) 2, MMP9, and vimentin was decreased after HuR knockdown. Moreover, silencing of HuR disturbed the cell cycle of ESCC cells mainly by inducing G1 arrest. Furthermore, proteomics analysis showed that downregulation of HuR in TE-1 cells resulted in 100 upregulated and 122 downregulated proteins, including IL-18 as a significantly upregulated protein. The expression of IL-18 was inversely regulated by HuR. IL-18 expression was decreased in ESCC tissues, and exogenous IL-18 significantly inhibited the proliferation and metastasis of ESCC cells. The 3'-UTR of IL-18 harbored a HuR binding site, as shown by an in vitro luciferase assay.
Conclusion
HuR plays an important role in the progression of esophageal carcinoma by targeting IL-18, which may be a potential therapeutic target for the treatment of ESCC.

Citations

Citations to this article as recorded by  
  • Mechanistic insights into the antitumoral potential and in vivo antiproliferative efficacy of a silver-based core@shell nanosystem
    Guillermo Aragoneses-Cazorla, Roberto Alvarez-Fernandez Garcia, Angelica Martinez-Lopez, Milagros Gomez Gomez, Maria Vallet-Regí, Sonia Castillo-Lluva, Blanca González, Jose L. Luque-Garcia
    International Journal of Pharmaceutics.2024; 655: 124023.     CrossRef
  • Blocking SLC7A11 attenuates the proliferation of esophageal squamous cell carcinoma cells
    Wen-Ting Li, Xin Jin, Sheng-Jie Song, Chong Wang, Chuang Fu, Wen Jiang, Jie Bai, Zhi-Zhou Shi
    Animal Cells and Systems.2024; 28(1): 237.     CrossRef
  • Editorial: Radiotherapy for esophageal cancer: Molecular mechanism and novel targets to improve radiosensitivity
    Yanqing Liu, Adam Yongxin Ye, Jordan Lu, Jiaxing Yang, Xiao Zheng, Xiaodong Li
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • HuR Affects the Radiosensitivity of Esophageal Cancer by Regulating the EMT-Related Protein Snail
    Yan Hu, Qing Li, Ke Yi, Chi Yang, Qingjun Lei, Guanghui Wang, Qianyun Wang, Xiaohui Xu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Identification of a Novel Pyroptosis-Related Gene Signature Indicative of Disease Prognosis and Treatment Response in Skin Cutaneous Melanoma
    An-An Li, Yu Zhang, Wei-Lai Tong, Jiang-Wei Chen, Shan-Hu Huang, Jia-Ming Liu, Zhi-Li Liu
    International Journal of General Medicine.2022; Volume 15: 6145.     CrossRef
  • MicroRNAs, Tristetraprolin Family Members and HuR: A Complex Interplay Controlling Cancer-Related Processes
    Cyril Sobolewski, Laurent Dubuquoy, Noémie Legrand
    Cancers.2022; 14(14): 3516.     CrossRef
  • The role of human antigen R (HuR) in modulating proliferation, senescence and radiosensitivity of skin cells
    Daojiang Yu, Yahui Feng, Zhiqiang Jiang, Tao Yan, Kai Fang, Yuhong Shi, Jie Zhang, Shuyu Zhang
    Experimental and Therapeutic Medicine.2022;[Epub]     CrossRef
  • IFI35 is involved in the regulation of the radiosensitivity of colorectal cancer cells
    Yan Hu, Bing Wang, Ke Yi, Qingjun Lei, Guanghui Wang, Xiaohui Xu
    Cancer Cell International.2021;[Epub]     CrossRef
  • LncRNA BBOX1‐AS1 upregulates HOXC6 expression through miR‐361‐3p and HuR to drive cervical cancer progression
    Jun Xu, Baohua Yang, Lifeng Wang, Yunheng Zhu, Xiuxiang Zhu, Ziyin Xia, Zhen Zhao, Ling Xu
    Cell Proliferation.2020;[Epub]     CrossRef
  • Angustoline Inhibited Esophageal Tumors Through Regulating LKB1/AMPK/ELAVL1/LPACT2 Pathway and Phospholipid Remodeling
    Huiying Li, Cheng Zhang, Min Zhang, Qianqian Yao, Huaigu Yang, Linlin Fan, Nan Zheng
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • The RNA‐Binding Protein HuR in Digestive System Tumors
    Xiaoqing Song, Xin Shi, Wenjuan Li, Fa Zhang, Zhonglin Cai, Goutam Ghosh Choudhury
    BioMed Research International.2020;[Epub]     CrossRef
  • Proteogenomic examination of esophageal squamous cell carcinoma (ESCC): new lines of inquiry
    Shobha Dagamajalu, Manavalan Vijayakumar, Rohan Shetty, D. A. B. Rex, Chinmaya Narayana Kotimoole, T. S. Keshava Prasad
    Expert Review of Proteomics.2020; 17(9): 649.     CrossRef
  • Interleukin-18 Is a Prognostic Marker and Plays a Tumor Suppressive Role in Colon Cancer
    Xiaodong Feng, Zhijun Zhang, Peng Sun, Guanghui Song, Lu Wang, Zhenqing Sun, Ning Yuan, Qing Wang, Limin Lun, Roberta Rizzo
    Disease Markers.2020; 2020: 1.     CrossRef
  • Proteomics in Drug Development: The Dawn of a New Era?
    Maria Frantzi, Agnieszka Latosinska, Harald Mischak
    PROTEOMICS – Clinical Applications.2019;[Epub]     CrossRef
  • IL-33 in the tumor microenvironment is associated with the accumulation of FoxP3-positive regulatory T cells in human esophageal carcinomas
    Guanglin Cui, Zhenfeng Li, Jingli Ren, Aping Yuan
    Virchows Archiv.2019; 475(5): 579.     CrossRef
  • The Multifaceted Roles of Pyroptotic Cell Death Pathways in Cancer
    Man Wang, Shuai Jiang, Yinfeng Zhang, Peifeng Li, Kun Wang
    Cancers.2019; 11(9): 1313.     CrossRef
  • Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells
    Zili Zhang, Zhen Yao, Ling Wang, Hai Ding, Jiangjuan Shao, Anping Chen, Feng Zhang, Shizhong Zheng
    Autophagy.2018; 14(12): 2083.     CrossRef
  • Deficiency of IL-18 Aggravates Esophageal Carcinoma Through Inhibiting IFN-γ Production by CD8+T Cells and NK Cells
    Jiantao Li, Gang Qiu, Baoshuan Fang, Xiaohui Dai, Jianhui Cai
    Inflammation.2018; 41(2): 667.     CrossRef
  • 11,802 View
  • 300 Download
  • 22 Web of Science
  • 18 Crossref
Close layer
Case Report
A Rare Case of Phyllodes Tumor Metastasis to the Stomach Presenting as Anemia
Do Il Choi, Ho Seok Chi, Sang Ho Lee, Youngmee Kwon, Seog Yun Park, Sung Hoon Sim, In Hae Park, Keun Seok Lee
Cancer Res Treat. 2017;49(3):846-849.   Published online September 1, 2016
DOI: https://doi.org/10.4143/crt.2016.188
AbstractAbstract PDFPubReaderePub
Metastasis of a phyllodes tumor to the stomach is an extremely rare condition with important clinical implications. A 44-year-old woman was initially diagnosed with a phyllodes tumor in her right breast in 2008, and subsequently presented to an outpatient clinic with dizziness on December 16, 2013. We found that she had severe anemia (hemoglobin levels, 6.7 g/dL), and we quickly performed esophagogastroduodenoscopy to identify the cause. This procedure revealed large ulcerofungating masses with active bleeding in the stomach. Histopathological examination revealed that the masses were consistent with phyllodes tumor metastases. In patients with a metastatic phyllodes tumor presenting as anemia, gastric metastasis should be considered as one of the differential diagnoses because overlooking the possibility might have dire consequences if cytotoxic chemotherapy were administered.

Citations

Citations to this article as recorded by  
  • Unusual Metastatic Sites in Malignant Phyllodes Tumor Detected on FDG PET/CT
    Wai Ip Li, Koon Kiu Ng, Ting Kun Au Yong, Boom Ting Kung
    World Journal of Nuclear Medicine.2024; 23(02): 147.     CrossRef
  • NKILA is a novel suppressor of local recurrence in women breast malignant phyllodes tumor patients via inhibition of the NF-κB pathway
    Ying Mi, Le Yan, Haiyun Jin, Ming Jin, Di Zhu, Hongyan Huang, Kai Han, Jibo Huang
    Heliyon.2024; 10(13): e33259.     CrossRef
  • A rare case of metastatic malignant phyllodes tumor with osteosarcomatous differentiation presenting with intestinal obstruction
    Neelam R. Bhandari, Manjusha M. Karegar, Pradeep Vaideeswar
    Indian Journal of Pathology and Microbiology.2023; 66(1): 184.     CrossRef
  • Clinical perspectives and outcomes of the giant breast phyllodes tumor and sarcoma: a real-world retrospective study
    Naiquan Liu, Ye Kang, Ningxin Qu, Chenhui Kong, Ye Han
    BMC Cancer.2023;[Epub]     CrossRef
  • Metastasis to the stomach: a systematic review
    Arturan Ibrahimli, Altay Aliyev, Aykhan Majidli, Aysegul Kahraman, Aysuna Galandarova, Emil Khalilzade, Heydar Mammadli, Kamran Huseynli, Karam Assaf, Cagatay Kilinc, Nijat Muradov, Omer F. Alisan, Sabir Abdullayev, Yeliz I. Sahin, Elgun Samadov
    F1000Research.2023; 12: 1374.     CrossRef
  • Significant Antitumor Activity of Pazopanib in a Patient with PDGFRB-Mutated Metastatic Phyllodes Tumor: a Case Report
    Mieko Ochi, Shingo Miyamoto, Keita Nakao, Yoshiaki Furuhata, Yusuke Tabei, Shunsuke Ichi, Yuan Bae, Toshio Kumasaka, Shingo Kato, Hideo Kunitoh
    SN Comprehensive Clinical Medicine.2021; 3(3): 901.     CrossRef
  • Malignant phyllodes tumor of the breast: case report, tumor characteristics, treatment approach
    Łukasz Strzępek, Patrycja Ciesielska, Katarzyna Karakiewicz-Krawczyk, Aleksandra Czerw
    Breast Cancer Management.2021;[Epub]     CrossRef
  • A giant malignant phyllodes tumor of breast post mastectomy with metastasis to stomach manifesting as anemia: a case report and review of literature
    Hui-Pu Liu, Wen-Yen Chang, Chin-Wen Hsu, Shan-Tao Chien, Zheng-Yi Huang, Wen-Ching Kung, Ping-Hung Liu
    BMC Surgery.2020;[Epub]     CrossRef
  • Distant metastases in phyllodes tumours of the breast: an overview
    Valerie Cui Yun Koh, Aye Aye Thike, Puay Hoon Tan
    Applied Cancer Research.2017;[Epub]     CrossRef
  • Atypical Distant Metastasis of Breast Malignant Phyllodes Tumors: A Case Report and Literature Review
    Tiphaine de Foucher, Hélène Roussel, Mikael Hivelin, Léa Rossi, Caroline Cornou, Anne-Sophie Bats, Myriam Deloménie, Fabrice Lécuru, Charlotte Ngô
    Case Reports in Obstetrics and Gynecology.2017; 2017: 1.     CrossRef
  • 10,211 View
  • 180 Download
  • 10 Web of Science
  • 10 Crossref
Close layer
Original Articles
Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer
Kyu-pyo Kim, Jeong-Eun Kim, Yong Sang Hong, Sung-Min Ahn, Sung Min Chun, Seung-Mo Hong, Se Jin Jang, Chang Sik Yu, Jin Cheon Kim, Tae Won Kim
Cancer Res Treat. 2017;49(1):161-167.   Published online July 4, 2016
DOI: https://doi.org/10.4143/crt.2015.490
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Although the mutation status of KRAS is highly concordant in primary and metastatic lesions, it has not been generalized to other major pathway genes.
Materials and Methods
In this study, 41 genes were evaluated and the mutational profiles were compared in 46 colorectal cancer patients with paired surgical specimens of primary and metastatic lesions: synchronous (n=27) and metachronous (n=19) lesions. A high-throughput mass spectrometry-based genotyping platform validated by orthogonal chemistry, OncoMap v.4.4, was used to evaluate the formalin-fixed, paraffin-embedded surgical specimens. The patients’ demographics, tumor characteristics, and microsatellite instability status were analyzed by a retrospective chart review.
Results
In this study,with OncoMap, mutationswere identified in 80.4% of patientswith the following frequency: KRAS (39.1%), TP53 (28.3%), APC (28.3%), PIK3CA (6.5%), BRAF (6.5%), and NRAS (4.3%). Although 19.6% (9/46) of the patients showed no gene mutations, 43.5% (20/46) and 37.0% (17/46) had mutations in one and two or more genes, respectively. The synchronous and metachronous lesions showed similar mutational profiles. Paired samples between primary and metastatic tumors differed in 7.4% (2/27) and 10.5% (2/19) for synchronous and metachronous according to OncoMap.
Conclusion
These findings indicate the major pathway genes, including KRAS, TP53, APC, PIK3CA, BRAF, and NRAS, are often concordant between the primary and metastatic lesions regardless of the temporal relationship of metastasis.

Citations

Citations to this article as recorded by  
  • Analysis of Shared Variants between Cancer Biospecimens
    Michael B. Foote, James Robert White, Walid K. Chatila, Guillem Argilés, Steve Lu, Benoit Rousseau, Oliver Artz, Paul Johannet, Henry Walch, Mitesh Patel, Michelle F. Lamendola-Essel, David Casadevall, Somer Abdelfattah, Shrey Patel, Rona Yaeger, Andrea C
    Clinical Cancer Research.2025; 31(2): 376.     CrossRef
  • Mutation characteristics and molecular evolution of ovarian metastasis from gastric cancer and potential biomarkers for paclitaxel treatment
    Pengfei Yu, Can Hu, Guangyu Ding, Xiaoliang Shi, Jingli Xu, Yang Cao, Xiangliu Chen, Wei Wu, Qi Xu, Jingquan Fang, Xingmao Huang, Shaohua Yuan, Hui Chen, Zhizheng Wang, Ling Huang, Fei Pang, Yian Du, Xiangdong Cheng
    Nature Communications.2024;[Epub]     CrossRef
  • The varied clonal trajectory of liver and lung metastases of colorectal cancer
    Ofer N. Gofrit, Ben Gofrit, S. Nahum Goldberg, Aron Popovtzer, Jacob Sosna, Ayala Hubert
    Advances in Cancer Biology - Metastasis.2024; 11: 100122.     CrossRef
  • Whole-Exome Sequencing Reveals High Mutational Concordance between Primary and Matched Recurrent Triple-Negative Breast Cancers
    Jaspreet Kaur, Darshan S. Chandrashekar, Zsuzsanna Varga, Bettina Sobottka, Emiel Janssen, Khanjan Gandhi, Jeanne Kowalski, Umay Kiraz, Sooryanarayana Varambally, Ritu Aneja
    Genes.2023; 14(9): 1690.     CrossRef
  • The different clonal origins of metachronous and synchronous metastases
    Ofer N. Gofrit, Ben Gofrit, Yuval Roditi, Aron Popovtzer, Steve Frank, Jacob Sosna, Marina Orevi, S. Nahum Goldberg
    Journal of Cancer Research and Clinical Oncology.2023; 149(13): 11085.     CrossRef
  • Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish
    Ruba Hamed, Sam Marks, Helen Mcelligott, Roshni Kalachand, Hawa Ibrahim, Said Atyani, Greg Korpanty, Nemer Osman
    Molecular and Clinical Oncology.2021;[Epub]     CrossRef
  • Association of DNA repair gene polymorphisms with colorectal cancer risk and treatment outcomes
    Fawaz N. Al-Shaheri, Kamal M. Al-Shami, Eshrak H. Gamal, Amjad A. Mahasneh, Nehad M. Ayoub
    Experimental and Molecular Pathology.2020; 113: 104364.     CrossRef
  • High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases
    Tuva Høst Brunsell, Anita Sveen, Bjørn Atle Bjørnbeth, Bård I. Røsok, Stine Aske Danielsen, Kristoffer Watten Brudvik, Kaja C.G. Berg, Bjarne Johannessen, Vanja Cengija, Andreas Abildgaard, Marianne Grønlie Guren, Arild Nesbakken, Ragnhild A. Lothe
    Clinical Colorectal Cancer.2020; 19(1): e26.     CrossRef
  • Case report: recurrent pituitary adenoma has increased load of somatic variants
    Raitis Peculis, Inga Balcere, Ilze Radovica-Spalvina, Ilze Konrade, Olivija Caune, Kaspars Megnis, Vita Rovite, Janis Stukens, Jurijs Nazarovs, Austra Breiksa, Aigars Kiecis, Ivars Silamikelis, Valdis Pirags, Janis Klovins
    BMC Endocrine Disorders.2020;[Epub]     CrossRef
  • Transcriptomic analysis by RNA sequencing characterises malignant progression of canine insulinoma from normal tissue to metastatic disease
    Y. Capodanno, F. O. Buishand, L. Y. Pang, J. Kirpensteijn, J. A. Mol, R. Elders, D. J. Argyle
    Scientific Reports.2020;[Epub]     CrossRef
  • Genetic Alterations of Metastatic Colorectal Cancer
    Ugo Testa, Germana Castelli, Elvira Pelosi
    Biomedicines.2020; 8(10): 414.     CrossRef
  • Prognostic impact of the Fusobacterium nucleatum status in colorectal cancers
    Yanglong Chen, Ying Lu, Yuting Ke, Yanling Li
    Medicine.2019; 98(39): e17221.     CrossRef
  • Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer
    Camille Evrard, Gaëlle Tachon, Violaine Randrian, Lucie Karayan-Tapon, David Tougeron
    Cancers.2019; 11(10): 1567.     CrossRef
  • Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting
    William Hankey, Wendy L. Frankel, Joanna Groden
    Cancer and Metastasis Reviews.2018; 37(1): 159.     CrossRef
  • Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells
    Ugo Testa, Elvira Pelosi, Germana Castelli
    Medical Sciences.2018; 6(2): 31.     CrossRef
  • Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-naïve advanced non-squamous non-small cell lung cancer patients
    Fangfang Xie, Yujun Zhang, Xiaowei Mao, Xiaoxuan Zheng, Han Han-Zhang, Junyi Ye, Ruiying Zhao, Xueyan Zhang, Jiayuan Sun
    Lung Cancer.2018; 121: 54.     CrossRef
  • Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer
    Georgios Antonios Margonis, Stefan Buettner, Nikolaos Andreatos, Yuhree Kim, Doris Wagner, Kazunari Sasaki, Andrea Beer, Christoph Schwarz, Inger Marie Løes, Maria Smolle, Carsten Kamphues, Jin He, Timothy M. Pawlik, Klaus Kaczirek, George Poultsides, Per
    JAMA Surgery.2018; 153(7): e180996.     CrossRef
  • Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
    Chiara Molinari, Giorgia Marisi, Alessandro Passardi, Laura Matteucci, Giulia De Maio, Paola Ulivi
    International Journal of Molecular Sciences.2018; 19(12): 3733.     CrossRef
  • 10,508 View
  • 279 Download
  • 20 Web of Science
  • 18 Crossref
Close layer
Prediction of Lymph Node Metastasis by Tumor Dimension Versus Tumor Biological Properties in Head and Neck Squamous Cell Carcinomas
Jeon Yeob Jang, Min Ji Kim, Gwanghui Ryu, Nayeon Choi, Young-Hyeh Ko, Han-Sin Jeong
Cancer Res Treat. 2016;48(1):54-62.   Published online March 6, 2015
DOI: https://doi.org/10.4143/crt.2014.332
AbstractAbstract PDFPubReaderePub
Purpose
Lymph node metastasis (LNM) is a strong prognostic factor in many solid cancers, including head and neck squamous cell carcinomas (HNSCC), and LNM can be dependent upon primary tumor biology, as well as tumor dimension. Here, we investigate the relative risk of LNM in accordance to tumor dimension and biology in HNSCC subsites.
Materials and Methods
Medical data of 295 HNSCC patients who had undergone the initial curative surgery (oral tongue 174, oropharynx 75, hypopharynx 46) were analyzed to identify the significant predictive factor for LNM. Tumor volume and thickness were set as tumor dimensional variables, and biological variables included lymphovascular, perineural invasion, and tumor differentiation. Statistical analyses were conducted to assess the predictability of LNM from variables, and subgroup analyses according to the tumor subsites. In addition, we evaluated the impacts of tumor dimension and biological variables on the treatment outcomes and survival in HNSCC subsites.
Results
The overall tumor dimension and biological variables had a similar impact on the prediction of LNM in HNSCC (area under curve, 0.7682 and 0.7717). The prediction sensitivity of LNM in oral tongue cancer was mainly dependent on tumor dimension, while LNM in oro- and hypo-pharynx cancers was more influenced by biological factors. Survival analyses also confirmed that biological factor was more powerful in estimating disease-free survival of hypopharyngeal cancer patients, while tumor dimension was more significant in that of oral cancer patients.
Conclusion
Tumor dimension and biology have a significant, tumor subsite-dependent impact on the occurrence of LNM and disease-free survival in HNSCC.

Citations

Citations to this article as recorded by  
  • Extra-Capsular Spread of Lymph Node Metastasis in Oral, Oropharyngeal and Hypopharyngeal Cancer: A Comparative Subsite Analysis
    Yung Jee Kang, Goeun Park, Sung Yool Park, Taehwan Kim, Eunhye Kim, Yujin Heo, Changhee Lee, Han-Sin Jeong
    Cancers.2024; 16(3): 659.     CrossRef
  • The Prognostic Role of Perineural Invasion for Survival in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
    Zhuo-Ying Tao, Guang Chu, Yu-Xiong Su
    Cancers.2024; 16(14): 2514.     CrossRef
  • A preoperative nomogram model for the prediction of lymph node metastasis in buccal mucosa cancer
    Qian Chen, Rui Wei, Shan Li
    Cancer Medicine.2023; 12(13): 14120.     CrossRef
  • The Prognostic Prediction Value of Positive Lymph Nodes Numbers for the Hypopharyngeal Squamous Cell Carcinoma
    Wendu Pang, Yaxin Luo, Junhong Li, Danni Cheng, Yufang Rao, Minzi Mao, Ke Qiu, Yijun Dong, Jun Liu, Jian Zou, Haiyang Wang, Fei Chen
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Crosstalk between head and neck cancer cells and lymphatic endothelial cells promotes tumor metastasis via CXCL5‐CXCR2 signaling
    Bok‐Soon Lee, Jeon Yeob Jang, Chorong Seo, Chul‐Ho Kim
    The FASEB Journal.2021;[Epub]     CrossRef
  • A nomogram for predicting occult lymph node metastasis in early hypopharyngeal cancer with cN0
    Xiaohui Yuan, Chi-Yao Hsueh, Ming Zhang, Lei Tao, Liang Zhou
    European Archives of Oto-Rhino-Laryngology.2021; 278(9): 3515.     CrossRef
  • Individualized elective irradiation of the clinically node‐negative neck in definitive radiotherapy for head and neck squamous cell carcinoma
    Jia Kou, Li Lin, Cheng‐Yang Jiao, Meng‐Qiu Tian, Guan‐Qun Zhou, Xue Jiang, Jun Ma, Zhen‐Yu Qi, Yao Lu, Ying Sun
    Cancer Communications.2021; 41(4): 303.     CrossRef
  • The prognostic value of tumor depth for cervical lymph node metastasis in hypopharyngeal and supraglottic carcinomas
    Lu‐Lu Ye, Jia Rao, Xing‐Wen Fan, Fang‐Fang Kong, Chao‐Su Hu, Hong‐Mei Ying
    Head & Neck.2019; 41(7): 2116.     CrossRef
  • Patients with unilateral squamous cell carcinoma of the tongue and ipsilateral lymph node metastasis do not profit from bilateral neck dissection
    Christoph Klingelhöffer, Andreas Gründlinger, Gerrit Spanier, Stephan Schreml, Maximilian Gottsauner, Steffen Mueller, Johannes K. Meier, Torsten E. Reichert, Tobias Ettl
    Oral and Maxillofacial Surgery.2018; 22(2): 185.     CrossRef
  • Comparison of tumor volume, thickness, and T classification as predictors of outcomes in surgically treated squamous cell carcinoma of the oral tongue
    Manish Mair, Deepa Nair, Sudhir Nair, Akshat Malik, Aseem Mishra, Sadhana Kannan, Saurabh Bobdey, Hitesh Singhvi, Pankaj Chaturvedi
    Head & Neck.2018; 40(8): 1667.     CrossRef
  • pN status predicts outcomes in surgically treated pT1–pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study
    Xu Qian, Branko Sinikovic, Frank Schreiber, Sebastian Ochsenreither, Konrad Klinghammer, Barbara Wollenberg, Andreas M. Kaufmann, Andreas E. Albers
    European Archives of Oto-Rhino-Laryngology.2018; 275(11): 2787.     CrossRef
  • Predictive markers for delayed lymph node metastases and survival in early-stage oral squamous cell carcinoma
    Ivica Luksic, Petar Suton
    Head & Neck.2017; 39(4): 694.     CrossRef
  • Measurement of tumor volume is not superior to diameter for prediction of lymph node metastasis in early gastric cancer with minute submucosal invasion
    Jeung Hui Pyo, Sun-Ju Byeon, Hyuk Lee, Yang Won Min, Byung-Hoon Min, Jun Haeng Lee, Kyoung-Mee Kim, Hyeon Seon Ahn, Kyunga Kim, Yoon-Ho Choi, Jae J. Kim
    Oncotarget.2017; 8(69): 113758.     CrossRef
  • Mechanisms of Lymph Node Metastasis in Head and Neck Cancer
    Jeon Yeob Jang
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2016; 59(4): 259.     CrossRef
  • Analysis of angiogenic markers in oral squamous cell carcinoma-gene and protein expression
    Susanne Jung, Sonja Sielker, Nikolai Purcz, Christoph Sproll, Yahya Acil, Johannes Kleinheinz
    Head & Face Medicine.2015;[Epub]     CrossRef
  • 13,425 View
  • 131 Download
  • 15 Web of Science
  • 15 Crossref
Close layer
Case Report
Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib
Youngmok Park, Hyemin Kim, Eui-Hyun Kim, Chang-Ok Suh, Soohyeon Lee
Cancer Res Treat. 2016;48(1):403-408.   Published online February 16, 2015
DOI: https://doi.org/10.4143/crt.2014.165
AbstractAbstract PDFPubReaderePub
Brain metastasis affects one third of patients with HER2-positive breast cancer after treatment with trastuzumab. Surgical resection and radiation therapy are often unsuccessful at accomplishing complete control of metastasis. Lapatinib is presumed to cross the blood-brain barrier, and exhibits clinical activities for treatment of HER2- positive breast cancer. A 43-year-old woman was treated for early breast carcinoma with total mastectomy, axillary lymph-node dissection, and adjuvant chemotherapy with cyclophosphamide plus doxorubicin. After the end of adjuvant trastuzumab therapy, she was diagnosed with panhypopituitarism due to pituitary metastasis. Surgical removal and whole brain radiation therapy were performed, but a portion of viable tumor remained. Only taking lapatinib, the size of the metastatic lesion began to shrink. Trastuzumab may have controlled the micro-metastasis of breast cancer, but it was unable to control its progression to the central nervous system. Lapatinib is a possible option for HER2-positive metastatic breast cancer patients with brain metastasis.

Citations

Citations to this article as recorded by  
  • Breast cancer metastasis in sellar and suprasellar region. A rare presentation, and the ideal clinical management
    Tiago Holanda, Isnara Mara Freitas Pimentel, Lucas Alverne Freitas de Albuquerque
    Interdisciplinary Neurosurgery.2024; 36: 101923.     CrossRef
  • Differential Diagnosis in Hypophysitis: First Report on a Spindle Cell Rhabdomyosarcoma of the Pituitary Gland
    Hajrullah Ahmeti, Eva Jüttner, Christoph Röcken, Olav Jansen, Matthias Laudes, Michael Synowitz
    Journal of Neurological Surgery Part A: Central European Neurosurgery.2023; 84(03): 295.     CrossRef
  • Endonasal endoscopic approach for sellar metastatic pathologies: a national observation
    Gokmen Kahilogullari, Eyup Bayatli, Murat Geyik, Burak Cabuk, Suha Beton, Omur Gunaldi, Osman Tanrıverdi, Nuri Eralp Cetinalp, Ozgur Tarkan, Ali Erdem Yıldırım, Yahya Efe Guner, Ali Nehir, Ethem Goksu, Mahmut Akyuz, İlkay Isikay, Bulent Duz, Emrah Celtikc
    British Journal of Neurosurgery.2023; 37(2): 206.     CrossRef
  • Pituitary metastases: a case series and scoping review
    Kaiyun Yang, Sabrina L. Begley, Daniel Lynch, Vincent Ye, Jasleen Saini, Enrique Gutierrez, Jaclyn Vialet, Barbara-Ann Millar, Tatianna Conrad, Normand Laperriere, Mark Bernstein, Gelareh Zadeh, David B. Shultz, Paul N. Kongkham
    Pituitary.2023; 26(5): 538.     CrossRef
  • Early and isolated breast cancer metastasis to the pituitary: A case report and systematic review
    Neilen P Rasiah, Abdulrahman Albakr, Suzanne Kosteniuk, Yves Starreveld
    Surgical Neurology International.2022; 13: 462.     CrossRef
  • Pituitary Metastasis of Lung Neuroendocrine Carcinoma Mimicking Pituitary Adenoma:Case Report and Literature Review
    Xiaohai Liu, Renzhi Wang, Mingchu Li, Ge Chen
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Sellar Metastases
    Mostafa Shahein, Thiago Albonette-Felicio, Ricardo L. Carrau, Daniel M. Prevedello
    Neurosurgery Clinics of North America.2020; 31(4): 651.     CrossRef
  • Symptomatic Pituitary Metastasis as Initial Manifestation of Renal Cell Carcinoma: Case Report and Review of Literature
    Gunjan Y. Gandhi, Russell Fung, Patrick E. Natter, Raafat Makary, K. C. Balaji
    Case Reports in Endocrinology.2020; 2020: 1.     CrossRef
  • Clinical Presentation and Pathologic Characteristics of Pituitary Metastasis from Breast Carcinoma: Cases and a Systematic Review of the Literature
    Heng Cai, Wenjing Liu, Tianda Feng, Zhen Li, Yunhui Liu
    World Neurosurgery.2019; 124: 445.     CrossRef
  • Diagnosis, Therapy, and Therapeutic Effects in Cases of Pituitary Metastasis
    Yi Zhao, Wei Lian, Bing Xing, Ming Feng, Xiaohai Liu, Renzhi Wang, Weixun Zhou
    World Neurosurgery.2018; 117: 122.     CrossRef
  • Twelve cases of pituitary metastasis: a case series and review of the literature
    Mendel Castle-Kirszbaum, Tony Goldschlager, Benjamin Ho, Yi Yuen Wang, James King
    Pituitary.2018; 21(5): 463.     CrossRef
  • Pituitary metastasis: a rare condition
    Aida Javanbakht, Massimo D’Apuzzo, Behnam Badie, Behrouz Salehian
    Endocrine Connections.2018; 7(10): 1049.     CrossRef
  • Capecitabine/lapatinib/paclitaxel

    Reactions Weekly.2016; 1596(1): 49.     CrossRef
  • Unexpected Single Crystal Growth Induced by a Wire and New Crystalline Structures of Lapatinib
    Gabriel L. B. de Araujo, Matthias Zeller, Daniel Smith, Haichen Nie, Stephen R. Byrn
    Crystal Growth & Design.2016; 16(10): 6122.     CrossRef
  • Solitary Pituitary Metastasis of Advanced Breast Cancer Treated with Anti-Human Epidermal Growth Factor Receptor 2 Drug
    Jin Won Jang, Kyung Ae Lee, Won Sik Jung, Ja Yeon Lee, Sunghoon Choi, Yoon Chae Lee
    Soonchunhyang Medical Science.2015; 21(2): 110.     CrossRef
  • 12,583 View
  • 107 Download
  • 14 Web of Science
  • 15 Crossref
Close layer
Original Articles
Detecting Metastatic Bladder Cancer Using 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography
Hakan Öztürk
Cancer Res Treat. 2015;47(4):834-843.   Published online February 12, 2015
DOI: https://doi.org/10.4143/crt.2014.157
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to retrospectively investigate the contribution of 18F-fluorodeoxyglucose- positron emission tomography/computed tomography (18F-FDG-PET/CT) to detection of metastatic bladder cancer. Materials and Methods The present study included 79 patients (69 men and 10 women) undergoing 18F-FDGPET/ CT upon suspicion of metastatic bladder cancer between July 2007 and April 2013. The mean age was 66.1 years with a standard deviation of 10.7 years (range, 21 to 85 years). Patients were required to fast for 6 hours prior to scanning, and whole-body PET scanning from the skull base to the upper thighs was performed approximately 1 hour after intravenous injection of 555 MBq of 18F-FDG. Whole body CT scanning was performed in the cranio-caudal direction. FDG-PET images were reconstructed using CT data for attenuation correction. Suspicious recurrent or metastatic lesions were confirmed by histopathology or clinical follow-up. Results The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18F-FDG-PET/CT were 89%, 78%, 90%, 75%, and 86%, respectively. Conclusion 18F-FDG-PET/CT can detect metastases with high sensitivity and positive predictive values in patients with metastatic bladder carcinoma.

Citations

Citations to this article as recorded by  
  • Radiotherapy in metastatic bladder cancer
    Sophie Ashley, Ananya Choudhury, Peter Hoskin, YeePei Song, Priyamvada Maitre
    World Journal of Urology.2024;[Epub]     CrossRef
  • PET Imaging in Bladder Cancer: An Update and Future Direction
    Jules Zhang-Yin, Antoine Girard, Etienne Marchal, Thierry Lebret, Marie Homo Seban, Marine Uhl, Marc Bertaux
    Pharmaceuticals.2023; 16(4): 606.     CrossRef
  • Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy
    Olivier Fitoussi, Jean Baptiste Roche, Julien Riviere, Hervé Wallerand, Jean Eude Poulain, Pierre Gordien, Sigolène Galland, Bénédicte Henriques, Camille Dupin, Muriel Vincent, Thomas Kuratle, Mo Saffarini, Sonia Ramos-Pascual
    Urologia Internationalis.2023; 107(3): 239.     CrossRef
  • PET/CT in Bladder Cancer: An Update
    Kirsten Bouchelouche
    Seminars in Nuclear Medicine.2022; 52(4): 475.     CrossRef
  • Quantitative positron emission tomography imaging in the presence of iodinated contrast media using electron density quantifications from dual‐energy computed tomography
    Nadav Shapira, Joshua Scheuermann, Amy E. Perkins, Johoon Kim, Leening P Liu, Joel S. Karp, Peter B. Noël
    Medical Physics.2021; 48(1): 273.     CrossRef
  • 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in muscle-invasive bladder cancer
    Sarah M.H. Einerhand, Erik J. van Gennep, Laura S. Mertens, Kees Hendricksen, Maarten L. Donswijk, Henk G. van der Poel, Bas W.G. van Rhijn
    Current Opinion in Urology.2020; 30(5): 654.     CrossRef
  • The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma
    Antoine Girard, Helena Vila Reyes, Hiram Shaish, Jean-François Grellier, Laurent Dercle, Pierre-Yves Salaün, Olivier Delcroix, Mathieu Rouanne
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Cancers de la vessie
    A. Girard, J.F. Grellier, P.Y. Salaün
    Médecine Nucléaire.2019; 43(1): 69.     CrossRef
  • Comment on: Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer
    Antoine Girard, Mathieu Rouanne
    European Journal of Nuclear Medicine and Molecular Imaging.2019; 46(6): 1212.     CrossRef
  • Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study
    Fabio Zattoni, Elena Incerti, Michele Colicchia, Paolo Castellucci, Stefano Panareo, Maria Picchio, Federico Fallanca, Alberto Briganti, Marco Moschini, Andrea Gallina, Jeffrey R. Karnes, Val Lowe, Stefano Fanti, Riccardo Schiavina, Ilaria Rambaldi, Vince
    Abdominal Radiology.2018; 43(9): 2391.     CrossRef
  • The role of PET/CT in the evaluation of patients with urothelial cancer: a systematic review and meta-analysis
    Anna Rita Cervino, Lea Cuppari, Pasquale Reccia, Marta Burei, Giorgio Saladini, Laura Evangelista
    Clinical and Translational Imaging.2018; 6(2): 77.     CrossRef
  • Pelvic Lymph Node Staging by Combined 18 F-FDG-PET/CT Imaging in Bladder Cancer Prior to Radical Cystectomy
    Renate Pichler, Tobias De Zordo, Josef Fritz, Alexander Kroiss, Friedrich Aigner, Isabel Heidegger, Irene Virgolini, Wolfgang Horninger, Christian Uprimny
    Clinical Genitourinary Cancer.2017; 15(3): e387.     CrossRef
  • Metabolic coupling in urothelial bladder cancer compartments and its correlation to tumor aggressiveness
    Julieta Afonso, Lúcio L. Santos, António Morais, Teresina Amaro, Adhemar Longatto-Filho, Fátima Baltazar
    Cell Cycle.2016; 15(3): 368.     CrossRef
  • The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy
    William P. Parker, Philip L. Ho, Stephen A. Boorjian, Jonathan J. Melquist, Prabin Thapa, Jeffrey M. Holzbeierlein, Igor Frank, Ashish M. Kamat, Eugene K. Lee
    World Journal of Urology.2016; 34(11): 1561.     CrossRef
  • 15,401 View
  • 100 Download
  • 18 Web of Science
  • 14 Crossref
Close layer
Overexpression of Plasminogen Activator Inhibitor-1 in Advanced Gastric Cancer with Aggressive Lymph Node Metastasis
Yun-Suhk Suh, Jieun Yu, Byung Chul Kim, Boram Choi, Tae-Su Han, Hye Seong Ahn, Seong-Ho Kong, Hyuk-Joon Lee, Woo Ho Kim, Han-Kwang Yang
Cancer Res Treat. 2015;47(4):718-726.   Published online February 2, 2015
DOI: https://doi.org/10.4143/crt.2014.064
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to investigate differentially expressed genes using DNA microarray between advanced gastric cancer (AGC) with aggressive lymph node (LN) metastasis and that with a more advanced tumor stage but without LN metastasis.
Materials and Methods
Five sample pairs of gastric cancer tissue and normal gastric mucosa were taken from three patients with T3N3 stage (highN) and two with T4N0 stage (lowN). Data from triplicate DNA microarray experiments were analyzed, and candidate genes were identified using a volcano plot that showed ≥ 2-fold differential expression and were significant by Welch's t test (p < 0.05) between highN and lowN. Those selected genes were validated independently by reverse- transcriptase–polymerase chain reaction (RT-PCR) using five AGC patients, and tissue- microarray (TMA) comprising 47 AGC patients.
Results
CFTR, LAMC2, SERPINE2, F2R, MMP7, FN1, TIMP1, plasminogen activator inhibitor-1 (PAI- 1), ITGB8, SDS, and TMPRSS4 were commonly up-regulated over 2-fold in highN. REG3A, CD24, ITLN1, and WBP5 were commonly down-regulated over 2-fold in lowN. Among these genes, overexpression of PAI-1 was validated by RT-PCR, and TMA showed 16.7% (7/42) PAI-1 expression in T3N3, but none (0/5) in T4N0 (p=0.393).
Conclusion
DNA microarray analysis and validation by RT-PCR and TMA showed that overexpression of PAI-1 is related to aggressive LN metastasis in AGC.

Citations

Citations to this article as recorded by  
  • Expression of Serpin Family E Member 1 (SERPINE1) Is Associated with Poor Prognosis of Gastric Adenocarcinoma
    Jie Lv, Chunyang Yu, Hanhan Tian, Tao Li, Changhua Yu
    Biomedicines.2023; 11(12): 3346.     CrossRef
  • Helicobacter pylori-induced fibroblast-derived Serpin E1 promotes gastric cancer growth and peritoneal dissemination through p38 MAPK/VEGFA-mediated angiogenesis
    Wei Cheng, Yonghui Liao, Yuan Xie, Qinrong Wang, Leilei Li, Yuanjia Chen, Yan Zhao, Jianjiang Zhou
    Cancer Cell International.2023;[Epub]     CrossRef
  • Analysis of CFTR gene expression as an immunological and prognostic biomarker in pan-cancers
    Qi Wang, Shubing Jia, Jie Zheng, Rongwu Xiang, Yong Cui, Jinghai Zhang, Yijia Xu, Mingyi Zhao
    Computers in Biology and Medicine.2022; 146: 105614.     CrossRef
  • Interplay of Helicobacter pylori, fibroblasts, and cancer cells induces fibroblast activation and serpin E1 expression by cancer cells to promote gastric tumorigenesis
    Xueshu Chen, Wei Chen, Yan Zhao, Qinrong Wang, Wenling Wang, Yining Xiang, Hang Yuan, Yuan Xie, Jianjiang Zhou
    Journal of Translational Medicine.2022;[Epub]     CrossRef
  • SERBP1 affects the apoptotic level by regulating the expression and alternative splicing of cellular and metabolic process genes in HeLa cells
    Junjie Zhou, Wenhao Chen, Qianwen He, Dong Chen, Chunguang Li, Congqing Jiang, Zhao Ding, Qun Qian
    PeerJ.2022; 10: e14084.     CrossRef
  • A qualitative transcriptional signature of recurrence risk for stages II–III gastric cancer patients after surgical resection
    Huarong Zhang, Xiangyu Li, Junling Wu, Jiahui Zhang, Haiyan Huang, Yawei Li, Meifeng Li, Shanshan Wang, Jie Xia, Lishuang Qi, Ting Chen, Lu Ao
    Journal of Gastroenterology and Hepatology.2021; 36(9): 2501.     CrossRef
  • Weighted correlation network analysis identifies FN1, COL1A1 and SERPINE1 associated with the progression and prognosis of gastric cancer
    Qiaoyun Zhao, Jun Xie, Jinliang Xie, Rulin Zhao, Conghua Song, Huan Wang, Jianfang Rong, Lili Yan, Yanping Song, Fangfei Wang, Yong Xie
    Cancer Biomarkers.2021; 31(1): 59.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma
    Gary Tincknell, Ann-Katrin Piper, Morteza Aghmesheh, Therese Becker, Kara Lea Vine, Daniel Brungs, Marie Ranson
    Cancers.2021; 13(16): 4097.     CrossRef
  • Sustained postoperative plasma elevations of plasminogen activator inhibitor‑1 following minimally invasive colorectal cancer resection
    H.M.C. Kumara, Addison Poppy, Dasuni Gamage, Erica Pettke, Abhinit Shah, Xiaohong Yan, Vesna Cekic, Richard Whelan
    Molecular and Clinical Oncology.2021;[Epub]     CrossRef
  • High WBP5 expression correlates with elevation of HOX genes levels and is associated with inferior survival in patients with acute myeloid leukaemia
    C. Ward, P. Cauchy, P. Garcia, J. Frampton, M. A. Esteban, G. Volpe
    Scientific Reports.2020;[Epub]     CrossRef
  • microRNA‐501‐5p promotes cell proliferation and migration in gastric cancer by downregulating LPAR1
    Xiang Ma, Jiaxi Feng, Ming Lu, Wenjuan Tang, Jianbo Han, XiaGang Luo, Qinghong Zhao, Li Yang
    Journal of Cellular Biochemistry.2020; 121(2): 1911.     CrossRef
  • Adipocyte-Derived Leptin Promotes PAI-1-Mediated Breast Cancer Metastasis in a STAT3/miR-34a Dependent Manner
    Si-Jing Li, Xiao-Hui Wei, Xiao-Man Zhan, Jin-Yong He, Yu-Qi Zeng, Xue-Mei Tian, Sheng-Tao Yuan, Li Sun
    Cancers.2020; 12(12): 3864.     CrossRef
  • Global transcriptomic analysis identifiesSERPINE1as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer
    Bodong Xu, Zhigang Bai, Jie Yin, Zhongtao Zhang
    PeerJ.2019; 7: e7091.     CrossRef
  • Role of ion channels in gastrointestinal cancer
    Kyle J Anderson, Robert T Cormier, Patricia M Scott
    World Journal of Gastroenterology.2019; 25(38): 5732.     CrossRef
  • Clinicopathological and Prognostic Significance of WW Domain Binding Protein 5 Expression in Papillary Thyroid Carcinoma
    Yangyang Qian, Zongfu Pan, Zhenying Guo, Xinyang Ge, Guowan Zheng, Jun Cao, Ping Huang, Xin Zhu, Xuhang Zhu, Qingliang Wen, Minghua Ge
    BioMed Research International.2019; 2019: 1.     CrossRef
  • Cystic fibrosis transmembrane conductance regulator—emerging regulator of cancer
    Jieting Zhang, Yan Wang, Xiaohua Jiang, Hsiao Chang Chan
    Cellular and Molecular Life Sciences.2018; 75(10): 1737.     CrossRef
  • Identification of Potential Key Genes Associated With the Pathogenesis and Prognosis of Gastric Cancer Based on Integrated Bioinformatics Analysis
    Xinkui Liu, Jiarui Wu, Dan Zhang, Zhitong Bing, Jinhui Tian, Mengwei Ni, Xiaomeng Zhang, Ziqi Meng, Shuyu Liu
    Frontiers in Genetics.2018;[Epub]     CrossRef
  • The Expression and Significance of FAK/PI3K/AKt/mTOR Signaling Pathway Related Proteins in Human Gastric Carcinoma
    波 于
    World Journal of Cancer Research.2018; 08(03): 113.     CrossRef
  • Proteomic analysis of evodiamine-induced cytotoxicity in thyroid cancer cells
    Hui-I Yu, Hsiu-Chuan Chou, Yi-Ching Su, Li-Hsun Lin, Chieh-Hsiang Lu, Hsiang-Hsun Chuang, Yi-Ting Tsai, En-Chi Liao, Yu-Shan Wei, Yi-Ting Yang, Ying-Ray Lee, Hong-Lin Chan
    Journal of Pharmaceutical and Biomedical Analysis.2018; 160: 344.     CrossRef
  • Dynamic matrisome: ECM remodeling factors licensing cancer progression and metastasis
    Arseniy E. Yuzhalin, Su Yin Lim, Anton G. Kutikhin, Alex N. Gordon-Weeks
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2018; 1870(2): 207.     CrossRef
  • MicroRNA-200c binding to FN1 suppresses the proliferation, migration and invasion of gastric cancer cells
    Hengchun Zhang, Zhiguo Sun, Yan Li, Dong Fan, Hao Jiang
    Biomedicine & Pharmacotherapy.2017; 88: 285.     CrossRef
  • Methylation Levels of LINE-1 As a Useful Marker for Venous Invasion in Both FFPE and Frozen Tumor Tissues of Gastric Cancer
    Jimin Min, Boram Choi, Tae-Su Han, Hyuk-Joon Lee, Seong-Ho Kong, Yun-Suhk Suh, Tae-Han Kim, Hwi-Nyeong Choe, Woo Ho Kim, Keun Hur, Han-Kwang Yang
    Molecules and Cells.2017; 40(5): 346.     CrossRef
  • WW domain binding protein 5 induces multidrug resistance of small cell lung cancer under the regulation of miR-335 through the Hippo pathway
    Ruixiang Tang, Yingying Lei, Bingshuang Hu, Jie Yang, Shun Fang, Qiongyao Wang, Man Li, Linlang Guo
    British Journal of Cancer.2016; 115(2): 243.     CrossRef
  • Gastric cancer from operating theatre to bench in Korea
    H-K Yang
    British Journal of Surgery.2016; 103(10): 1251.     CrossRef
  • The embryonic stress response to in vitro culture: insight from genomic analysis
    Gael Cagnone, Marc-André Sirard
    Reproduction.2016; 152(6): R247.     CrossRef
  • 15,391 View
  • 163 Download
  • 27 Web of Science
  • 26 Crossref
Close layer
Extra-cranial Malignant Rhabdoid Tumor in Children: A Single Institute Experience
Che Ry Hong, Hyoung Jin Kang, Hee Young Ju, Ji Won Lee, Hyery Kim, Sung-Hye Park, Il Han Kim, Kyung Duk Park, Hee Young Shin
Cancer Res Treat. 2015;47(4):889-896.   Published online January 2, 2015
DOI: https://doi.org/10.4143/crt.2013.176
AbstractAbstract PDFPubReaderePub
Purpose
Malignant rhabdoid tumor (MRT) is a rare and highly aggressive tumor that affects young children. Due to its extreme rarity, most of the available data are based on retrospective case series. To add to the current knowledge of this disease, we reviewed the patients treated for extra-cranial MRT in our institute. Materials and Methods A retrospective medical record review was conducted on children treated for pathologically confirmed extra-cranial MRT at Seoul National University Children’s Hospital between January 2003 and May 2013. Results Eleven patients (7 boys, 4 girls) were diagnosed with extra-cranial MRT at a median age of 9 months old. INI1 staining was important in the pathological confirmation. Six patients (55%) had renal MRT and five (45%) had soft tissue MRT. Five patients (45%) had metastases at diagnosis. All patients underwent chemotherapy, eight patients (73%) underwent surgery, six patients (55%) received therapeutic radiotherapy, and four patients (36%) underwent high dose chemotherapy with autologous stem cell rescue (HDCT/ASCR) with melphalan, etoposide, and carboplatin. Five patients (45%) died of disease following progression (n=3) or relapse (n=2), however, there was no treatment related mortality. The overall survival of the cohort was 53.0% and the event-free survival was 54.5% with a median follow-up duration of 17.8 months (range, 2.3 to 112.3 months). Conclusion Extra-cranial MRT is still a highly aggressive tumor in young children. However, the improved survival of our cohort is promising and HDCT/ASCR with melphalan, etoposide, and carboplatin may be a promising treatment option.

Citations

Citations to this article as recorded by  
  • Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach
    Siqi Xie, Yuanyuan Fang, Yingying Yang, Lan Liu, Jianxi Bai, Sheng Lin, Bing Zhang, Yifan Fang
    European Journal of Pediatrics.2023; 183(2): 557.     CrossRef
  • Infantile Extracranial Rhabdoid Tumor of the Scalp
    Sura Al Rawabdeh, Deifallah Alsharari, Hayat Khasawneh, Ola M. Al Waqfi, Qamar Yaser Malabeh, Hiathem Abu Alhaija, Raed Mohammad Aljubour, Hamzeh M. Alkhawaldeh, Pablo Fernandez Pe as
    Case Reports in Medicine.2021; 2021: 1.     CrossRef
  • Pharmacokinetics of high-dose carboplatin in children undergoing high-dose chemotherapy and autologous stem cell transplantation with BSA-based dosing
    Che Ry Hong, Hyoung Jin Kang, Seol Ju Moon, Jaeseong Oh, Kyung Taek Hong, Jung Yoon Choi, Kyung-Sang Yu, Hee Young Shin
    Bone Marrow Transplantation.2020; 55(1): 137.     CrossRef
  • Successful Treatment of Extra‐Renal Noncerebral Rhabdoid Tumors with VIDE
    Naoko Yasui, Akihiko Yoshida, Eisuke Kobayashi, Fumihiko Nakatani, Hiroshi Kawamoto
    Pediatric Blood & Cancer.2016; 63(2): 352.     CrossRef
  • 14,575 View
  • 149 Download
  • 5 Web of Science
  • 4 Crossref
Close layer
Case Report
Bilateral Internal Auditory Canal Metastasis of Non-small Cell Lung Cancer
Chang-Hee Kim, Jung Eun Shin, Hee Joung Kim, Kye Young Lee
Cancer Res Treat. 2015;47(1):110-114.   Published online August 28, 2014
DOI: https://doi.org/10.4143/crt.2013.079
AbstractAbstract PDFPubReaderePub
We report on a patient with brain metastasis involving bilateral internal auditory canal from non-small cell lung cancer (NSCLC). A 49-year-old woman who had been diagnosed with NSCLC (T2aN1M0) complained of persistent vertigo and bilateral tinnitus for three months. The patient had refused all treatments, including surgery and chemotherapy; however, she sought alternative medicine. The patient’s hearing loss showed rapid progression bilaterally, and rotatory vertigo with peripheral-type nystagmus developed. Magnetic resonance imaging of the brain showed irregular nodular enhancement within both internal auditory canals with leptomeningeal enhancement and multiple intracranial metastasis. The patient was treated with epidermal growth factor receptor-tyrosine kinase inhibitor, and the tumor showed partial response. This was a rare case of multiple brain metastases involving bilateral internal auditory canal from known NSCLC presenting with vertigo and hearing loss.

Citations

Citations to this article as recorded by  
  • Imaging in sensorineural and conductive hearing loss—an educational review
    Edith Vassallo, Andre-Stefan Gatt, Reuben Grech, Serena Capasso, Ferdinando Caranci, Lorenzo Ugga
    La radiologia medica.2024;[Epub]     CrossRef
  • Direction-changing spontaneous nystagmus in cerebellopontine angle tumour
    Hamin Jeong, Dong-Han Lee, Jung Eun Shin, Chang-Hee Kim
    Journal of Clinical Neuroscience.2022; 95: 118.     CrossRef
  • Ear and Labyrinth Toxicities Induced by Immune Checkpoint Inhibitors: A Disproportionality Analysis from 2014 to 2019
    Fangyuan Hu, Xiaofei Ye, Yinghong Zhai, Jinfang Xu, Xiaojing Guo, Zhijian Guo, Xiang Zhou, Yiming Ruan, YongLong Zhuang, Jia He
    Immunotherapy.2020; 12(7): 531.     CrossRef
  • 13,987 View
  • 85 Download
  • 5 Web of Science
  • 3 Crossref
Close layer
Original Article
Analysis of the Prognostic Factors for Distant Metastasis after Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Head and Neck Cancer
Dong Hyun Kim, Won Taek Kim, Joo Hye Lee, Yong Kan Ki, Ji Ho Nam, Byung Joo Lee, Jin Choon Lee, Young Jin Choi, Young Mi Seol, Dong Won Kim
Cancer Res Treat. 2015;47(1):46-54.   Published online August 25, 2014
DOI: https://doi.org/10.4143/crt.2013.212
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this study is to identify the prognostic factors of distant metastasis (DM) after induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CRT) for locoregionally advanced head and neck cancer (HNC). Materials and Methods A total of 321 patients with HNC who underwent IC followed by CRT treated between January 2005 and December 2010 were analyzed retrospectively. IC consisted of three courses of docetaxel (70 mg/m2) and cisplatin (75 mg/m2) every three weeks, followed by radiotherapy of 66-70 Gy/2 Gy per fraction/5 fractions per week concurrent with weekly cisplatin (40 mg/m2). Tumor/nodal stage, primary site, tumor differentiation, lower neck node involvement (level IV, VB, and supraclavicular regions), number of concurrent chemotherapy cycles, overall duration of radiotherapy, and response to IC were assessed as potential prognostic factors influencing DM and survival outcome. Results The five-year loco-regional recurrence and DM rates were 23.6% and 18.2%. N stage, overall duration of radiotherapy, lower neck node involvement, and response to IC were significant factors for DM. With a median follow-up period of 52 months (range, 4 to 83 months), the 5-year progression-free, DM-free, and overall survival rates were 41.2%, 50.7%, and 55.1%, respectively. Lower neck node involvement (p=0.008) and poor response to IC (p < 0.001) showed an association with significantly inferior DM-free survival. Conclusion Even with the addition of IC, the DM rate and survival outcome were poor when metastatic lower neck lymph nodes were present or when patients failed to respond after receiving IC.

Citations

Citations to this article as recorded by  
  • Therapeutic Drug Monitoring of 5-Fluorouracil in Head and Neck Cancer Patients: An Interventional Pilot Study
    P. Sharmila Nirojini, N.K. Bhuvaneshwari, N. Dharsshini, S. Dhivya Bharathi, K. Velavan
    Indian Journal of Medical and Paediatric Oncology.2024; 45(02): 134.     CrossRef
  • An open, multicenter, exploratory study of apatinib mesylate maintenance therapy for recurrent/metastatic head and neck squamous cell carcinoma (ChiCTR1800019375)
    Jinlong Wei, Jing Su, Jianfeng Wang, Xiaojing Jia, Qin Zhao, Weiyan Shi, Huanhuan Wang, Zhuangzhuang Zheng, Xin Jiang
    Head & Neck.2024; 46(4): 915.     CrossRef
  • Current status of systemic therapy in head and neck cancer
    Abhenil Mittal, Atul Sharma
    Journal of Chemotherapy.2022; 34(1): 9.     CrossRef
  • Risk stratification of postoperative recurrence in hypopharyngeal squamous-cell carcinoma patients with nodal metastasis
    Hanqing Lin, Tian Wang, Yu Heng, Xiaoke Zhu, Liang Zhou, Ming Zhang, Yong Shi, Pengyu Cao, Lei Tao
    Journal of Cancer Research and Clinical Oncology.2021; 147(3): 803.     CrossRef
  • Clinical characteristics of head and neck cancers at a tertiary care hospital
    Sajid Durrani, Saleh Al-Dhahari, Haneen Sebeih, Tariq Wani, Khalid Al Qahatani, Humariya Heena
    Population Medicine.2020;[Epub]     CrossRef
  • Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy
    Simon Keek, Sebastian Sanduleanu, Frederik Wesseling, Reinout de Roest, Michiel van den Brekel, Martijn van der Heijden, Conchita Vens, Calareso Giuseppina, Lisa Licitra, Kathrin Scheckenbach, Marije Vergeer, C. René Leemans, Ruud H Brakenhoff, Irene Naut
    PLOS ONE.2020; 15(5): e0232639.     CrossRef
  • Induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancer: Single institution experience
    Or Dagan, Assaf Moore, Yuval Nachalon, Uri Alkan, Ameen Biadsee, Isaac Shochat, Aron Popovtzer
    Head & Neck.2020; 42(11): 3118.     CrossRef
  • Meta‐analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck
    Kimberley L. Kiong, Nurun Nisa de Souza, Rehena Sultana, N. Gopalakrishna Iyer
    The Laryngoscope.2018; 128(7): 1594.     CrossRef
  • Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions
    R.I. Haddad, M. Posner, R. Hitt, E.E.W. Cohen, J. Schulten, J.-L. Lefebvre, J.B. Vermorken
    Annals of Oncology.2018; 29(5): 1130.     CrossRef
  • Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief
    Andy Karabajakian, Max Gau, Thibault Reverdy, Eve-Marie Neidhardt, Jérôme Fayette
    Cancers.2018; 11(1): 15.     CrossRef
  • Revisiting Induction Chemotherapy Before Radiotherapy for Head and Neck Cancer, Part I: Carcinoma of Non-Nasopharyngeal Sites
    Christopher H Chapman, Upendra Parvathaneni, Sue S Yom
    Future Oncology.2017; 13(6): 469.     CrossRef
  • Predictors of Distant Metastasis after Radical Surgery Followed by Postoperative Radiotherapy with or without Chemotherapy for Oropharyngeal Cancer
    Mi Joo Chung, Yeon Sil Kim, Ji Yoon Kim, Yun Hee Lee, Ji Hyun Jang, Jin Hyoung Kang, Ie Ryung Yoo, Youn Soo Lee
    Cancer Research and Treatment.2016; 48(4): 1167.     CrossRef
  • The impact of treatment on quality of life of patients with head and neck cancer and its association with prognosis
    J.F. Carrillo, L.C. Carrillo, M.C. Ramirez-Ortega, F.J. Ochoa-Carrillo, L.F. Oñate-Ocaña
    European Journal of Surgical Oncology (EJSO).2016; 42(10): 1614.     CrossRef
  • Higher positive lymph node ratio indicates poorer distant metastasis–free survival in adenoid cystic carcinoma patients with nodal involvement
    Zhonglong Liu, Zao Fang, Tianguo Dai, Chenping Zhang, Jian Sun, Yue He
    Journal of Cranio-Maxillofacial Surgery.2015; 43(6): 751.     CrossRef
  • 13,059 View
  • 91 Download
  • 13 Web of Science
  • 14 Crossref
Close layer
Case Reports
Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma
Lee Chun Park, Ji Yun Jeong, Jun Ho Ji, Silvia Park, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat. 2014;46(2):200-203.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.200
AbstractAbstract PDFPubReaderePub

Cases of phenotypic heterogeneity of cells within tumors have recently been reported. Here, we report on a patient with characteristic intra-tumor double primary metastases in the lung. This patient was a 40-year-old Korean woman who had been diagnosed with breast cancer (T1N0M0, estrogen receptor/progesterone receptor/HER2 +/+/+) and papillary thyroid cancer three years prior and underwent a complete surgical resection followed by appropriate adjuvant treatment with radiation, hormone, and radioactive iodine. She was recently admitted for newly developed pulmonary nodules. Metastasectomy through video-assisted thoracoscopic surgery revealed recurrent double primary cancer with two different components (metastatic ductal carcinomas from the breast and metastatic papillary carcinomas from the thyroid gland) in each pulmonary nodule in the right upper lobe and right middle lobe. To the best of our knowledge, this is the first report of simultaneous recurrent double metastasis in one organ from different primary origins.

  • 11,898 View
  • 73 Download
  • 1 Web of Science
Close layer
Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease
Ho Cheol Kim, Jung Su Lee, Sang Hyung Kim, Hoon Sub So, Chang Yoon Woo, Jae Lyun Lee
Cancer Res Treat. 2013;45(4):349-353.   Published online December 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.4.349
AbstractAbstract PDFPubReaderePub
Von Hippel-Lindau (VHL) disease is an autosomal dominant disease that produces a variety of tumors and cysts in the central nervous system and visceral organs, including renal cell carcinoma (RCC). RCC in patients with VHL disease does not frequently metastasize, therefore, the response to treatment and prognosis of metastatic RCC developed in patients with VHL disease has not been reported. Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Here, we report on four patients with metastatic RCC in VHL disease who received sunitinib and achieved partial responses that have lasted for a prolonged period of time.

Citations

Citations to this article as recorded by  
  • The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?
    Alessandra Cinque, Roberto Minnei, Matteo Floris, Francesco Trevisani
    Cancers.2022; 14(21): 5352.     CrossRef
  • Hereditary renal cell tumors: Clinicopathologic importance
    Harmanjot Singh, Mukul K. Divatia, Donghwa Baek, Jae Y. Ro
    annals of urologic oncology.2021;[Epub]     CrossRef

  • Von Hippel-Lindau Disease: Current Challenges and Future Prospects


    Sven Gläsker, Evelynn Vergauwen, Christian A Koch, Alexander Kutikov, Alexander O Vortmeyer
    OncoTargets and Therapy.2020; Volume 13: 5669.     CrossRef
  • The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
    Song Peng, Jun Zhang, Xintao Tan, Yiqiang Huang, Jing Xu, Natalie Silk, Dianzheng Zhang, Qiuli Liu, Jun Jiang
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights
    Maria I. Carlo, A. Ari Hakimi, Grant D. Stewart, Gennady Bratslavsky, James Brugarolas, Ying-Bei Chen, W. Marston Linehan, Eamonn R. Maher, Maria J. Merino, Kenneth Offit, Victor E. Reuter, Brian Shuch, Jonathan A. Coleman
    European Urology.2019; 76(6): 754.     CrossRef
  • The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel–Lindau Disease: A Retrospective Study of 32 Patients
    Kaifang Ma, Baoan Hong, Jingcheng Zhou, Yanqing Gong, Jiangyi Wang, Shengjie Liu, Xiang Peng, Bowen Zhou, Jiufeng Zhang, Haibiao Xie, Kenan Zhang, Lei Li, Desheng Cai, Zixin Wang, Lin Cai, Kan Gong
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease
    Gang Yuan, Qiuli Liu, Dali Tong, Gaolei Liu, Yuting Yi, Jun Zhang, Yao Zhang, Lin-ang Wang, Luofu Wang, Rongrong Chen, Yanfang Guan, Xin Yi, Weihua Lan, Jun Jiang
    Cancer Biology & Therapy.2018; 19(9): 766.     CrossRef
  • Genetic Predisposition to Renal Cell Carcinoma: Implications for Counseling, Testing, Screening, and Management
    Brian Shuch, Jin Zhang
    Journal of Clinical Oncology.2018; 36(36): 3560.     CrossRef
  • A Case of von Hippel–Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas
    Su Jin Heo, Choong-kun Lee, Kyu Yeon Hahn, Gyuri Kim, Hyuk Hur, Sung Hoon Choi, Kyung Seok Han, Arthur Cho, Minkyu Jung
    Cancer Research and Treatment.2016; 48(1): 409.     CrossRef
  • Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease
    Akihiro Kobayashi, Masanobu Takahashi, Hiroo Imai, Shoko Akiyama, Shunsuke Sugiyama, Keigo Komine, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Naomi Sato, Fumiyoshi Fujishima, Taro Shuin, Hideki Shimodaira, Chikashi Ishioka
    Internal Medicine.2016; 55(6): 629.     CrossRef
  • Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group
    Stéphane Oudard, Reza Elaidi, Mara Brizard, Céline Le Rest, Valérie Caillet, Sophie Deveaux, Gérard Benoit, Jean-Michel Corréas, Farida Benoudiba, Philippe David, Alain Gaudric, Pascal Hammel, Dominique Joly, Marc Olivier Timsit, Arnaud Méjean, Stéphane R
    Oncotarget.2016; 7(51): 85306.     CrossRef
  • Pharmacogenomic biomarkers for personalized cancer treatment
    C. Rodríguez‐Antona, M. Taron
    Journal of Internal Medicine.2015; 277(2): 201.     CrossRef
  • Pharmacological HIF2α inhibition improves VHL disease–associated phenotypes in zebrafish model
    Ana Martins Metelo, Haley R. Noonan, Xiang Li, Youngnam Jin, Rania Baker, Lee Kamentsky, Yiyun Zhang, Ellen van Rooijen, Jordan Shin, Anne E. Carpenter, Jing-Ruey Yeh, Randall T. Peterson, Othon Iliopoulos
    Journal of Clinical Investigation.2015; 125(5): 1987.     CrossRef
  • Molecular and immunologic markers of kidney cancer—potential applications in predictive, preventive and personalized medicine
    Amanda Mickley, Olga Kovaleva, Julia Kzhyshkowska, Alexei Gratchev
    EPMA Journal.2015;[Epub]     CrossRef
  • 12,060 View
  • 70 Download
  • 15 Web of Science
  • 14 Crossref
Close layer
Original Article
Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis
Dong Soo Lee, Jin Hyoung Kang, Chang Geol Lee, Seoung Jun Kim, Young Jin Choi, Kyo Young Lee, Yeon Sil Kim
Cancer Res Treat. 2013;45(2):95-102.   Published online June 30, 2013
DOI: https://doi.org/10.4143/crt.2013.45.2.95
AbstractAbstract PDFPubReaderePub
PURPOSE
A number of factors related to overall survival (OS) have been addressed in advanced non-small cell lung cancer (NSCLC). This study was conducted to determine the impact of whole-body metastatic regions on survival outcome in advanced non-squamous NSCLC.
MATERIALS AND METHODS
Between March 2005 and February 2011, 112 eligible patients with newly confirmed stage IV non-squamous NSCLC, available for epidermal growth factor receptor (EGFR) mutation status 18-21 analysis, and accessible for the determination of pretreatment whole-body metastatic regions were enrolled in this retrospective study. The total number of synchronous metastatic regions was scored according to the following disease sites: abdomen/pelvis, lung to lung/pulmonary lymphangitic spread, bone, pleura/pleural effusion/pericardial effusion, neck/axillary lymph nodes, other soft tissue, brain.
RESULTS
The median age of the cohort was 65 years (range, 31 to 88 years). The median whole-body metastatic score was 2 (range, 1 to 6), and bone and lung to lung were the most common metastatic sites. EGFR mutations were observed in 40 (35.7%) patients with a deletion in exon 19 and Leu858Arg mutation in exon 21 being detected in 16 (40.0%) and 19 (47.5%) patients, respectively. Multivariate analysis for OS revealed that treatment factors (p=0.005), performance status (p=0.006), whole-body metastatic score (p<0.001), and EGFR mutation status (p=0.095) were significantly or marginally associated with OS.
CONCLUSION
The results of the present study demonstrated that whole-body metastatic extent strongly affects survival outcome, even after adjustment for other significant variables in advanced non-squamous NSCLC. The clinical validity of more curative multimodal approaches in cohorts with limited metastases remains to be explored.

Citations

Citations to this article as recorded by  
  • Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
    Boyeon Kim, Young Soo Park, Jae Sook Sung, Jong Won Lee, Saet Byeol Lee, Yeul Hong Kim
    Cancer Medicine.2021; 10(1): 372.     CrossRef
  • Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents
    Cláudia Freitas, Maria Jacob, Nuno Tavares, Natália Cruz-Martins, Conceição Souto-Moura, David Araújo, Hélder Novais-Bastos, Vanessa Santos, Gabriela Fernandes, Adriana Magalhães, Venceslau Hespanhol, Henrique Queiroga
    Anti-Cancer Drugs.2021; 32(5): 567.     CrossRef
  • O impacto da histologia do carcinoma pulmonar na frequência das metástases ósseas
    Marcelo Bragança dos Reis Oliveira, Larissa Costa Souza, Ermides Javier Garcia Sampayo, Gustavo Sobral de Carvalho, Fernanda Carvalho de Queiroz Mello, Marcos Eduardo Machado Paschoal
    Revista Brasileira de Ortopedia.2019; 54(05): 524.     CrossRef
  • Brain Metastases at Presentation in Patients With Non–Small Cell Lung Cancer
    Saiama N. Waqar, Sadaf H. Waqar, Kathryn Trinkaus, Carlos A. Gadea, Cliff G. Robinson, Jeffrey Bradley, Mark A. Watson, Varun Puri, Ramaswamy Govindan, Daniel Morgensztern
    American Journal of Clinical Oncology.2018; 41(1): 36.     CrossRef
  • Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer
    Lizet Sanchez, Leacky Muchene, Patricia Lorenzo-Luaces, Carmen Viada, Pedro C. Rodriguez, Sailyn Alfonso, Tania Crombet, Elia Neninger, Ziv Shkedy, Agustin Lage
    Seminars in Oncology.2018; 45(1-2): 52.     CrossRef
  • Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer
    Amanda Jane Williams Gibson, Haocheng Li, Adrijana D’Silva, Roxana A. Tudor, Anifat A. Elegbede, Shannon Mary Otsuka, D. Gwyn Bebb, Winson Y. Cheung
    Medical Oncology.2018;[Epub]     CrossRef
  • PATHOLOGICAL FRACTURES DUE TO BONE METASTASES FROM LUNG CANCER: RISK FACTORS AND SURVIVAL
    Marcelo Bragança dos Reis Oliveira, Bruno de Carvalho Marques, Rosa Aurílio Matos, César Rubens da Costa Fontenelle, Fernanda Carvalho de Queiroz Mello, Marcos Eduardo Machado Paschoal
    Acta Ortopédica Brasileira.2018; 26(6): 388.     CrossRef
  • Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes
    Dong Soo Lee, Kyung Ran Park, Seung Joon Kim, Mi Joo Chung, Yun Hee Lee, Ji Hyun Chang, Jin Hyoung Kang, Sook Hee Hong, Myung Sin Kim, Yeon Sil Kim
    Tumor Biology.2016; 37(1): 619.     CrossRef
  • Distinctive Patterns of Initially Presenting Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non-Small Cell Lung Cancer
    Dong Soo Lee, Yeon S. Kim, Chul S. Kay, Sung H. Kim, Chang D. Yeo, Jin W. Kim, Seung Joon Kim, Young K. Kim, Yoon H. Ko, Jin H. Kang, Kyo Y. Lee
    Medicine.2016; 95(6): e2795.     CrossRef
  • Rare occurrence of cavitation of lung metastases following effective targeted therapy: A case report
    JIACHENG SONG, JING YU, ZHANLONG MA, SHANSHAN LU
    Oncology Letters.2016; 11(2): 1589.     CrossRef
  • Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology
    Hatice Odabas, Arife Ulas, Kubra Aydin, Mevlude Inanc, Asude Aksoy, Dogan Yazilitas, Mehmet Turkeli, Sinemis Yuksel, Ali Inal, Ahmet S. Ekinci, Alper Sevinc, Nebi S. Demirci, Mukremin Uysal, Necati Alkis, Faysal Dane, Mehmet Aliustaoglu, Mahmut Gumus
    Tumor Biology.2015; 36(12): 9641.     CrossRef
  • Clinical Correlation Between Tumor Maximal Standardized Uptake Value in Metabolic Imaging and Metastatic Tumor Characteristics in Advanced Non-small Cell Lung Cancer
    Dong Soo Lee, Seung Joon Kim, Hong Seok Jang, Ie Ryung Yoo, Kyung Ran Park, Sae Jung Na, Kyo Young Lee, Sook Hee Hong, Jin Hyoung Kang, Young Kyoon Kim, Yeon Sil Kim
    Medicine.2015; 94(32): e1304.     CrossRef
  • A case of lung cancer complicated by axillary Castleman's disease
    Manabu Kakizoe, Kousuke Suzuki, Noriyuki Saeki
    The Journal of the Japanese Association for Chest Surgery.2015; 29(6): 722.     CrossRef
  • Non-small cell lung cancer metastasis to the oral cavity: a case report
    JB Olsen, F Sim, A Chandu
    Australian Dental Journal.2014; 59(4): 520.     CrossRef
  • Lung Cancer Coexisting With Ipsilateral Pleural Effusion
    Francisco Rodriguez-Panadero, Beatriz Romero-Romero
    Lung Cancer Management.2014; 3(4): 335.     CrossRef
  • EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
    Ukhyun Jo, Kyong Hwa Park, Young Mi Whang, Jae Sook Sung, Nam Hee Won, Jong Kuk Park, Yeul Hong Kim
    Oncotarget.2014; 5(5): 1265.     CrossRef
  • 11,403 View
  • 76 Download
  • 16 Crossref
Close layer
Case Report
Multiple Cardiac Metastases from a Nonfunctioning Pancreatic Neuroendocrine Tumor
Yong Hyeok Choi, Hye-Suk Han, Sung-Nam Lim, Sang Yeub Lee, Ji Hae Koo, Ok-Jun Lee, Ki Hyeong Lee, Seung Taik Kim
Cancer Res Treat. 2013;45(2):150-154.   Published online June 30, 2013
DOI: https://doi.org/10.4143/crt.2013.45.2.150
AbstractAbstract PDFPubReaderePub
Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms, which most commonly metastasize to the liver. However, intrathoracic metastases from pNETs are encountered infrequently. This report describes a case of nonfunctioning pNET with multiple cardiac metastases. A 56-year-old male presented with a palpable abdominal mass that showed progressive enlargement. Findings on computed tomography (CT) of the abdomen revealed two relatively well-marginated inhomogeneous low-attenuation masses, one in the head of the pancreas and the other in the tail. Multiple enhancing masses in the left pericardium with myocardial involvement were observed on chest CT and transthoracic echocardiography. Needle biopsies were performed on the mass in the tail of the pancreas and the left ventricular apical pericardium; histologic examination by hematoxylin and eosin morphology and immunohistochemical staining showed pNET in both. This is the first report of pNET with multiple cardiac metastases to previously undescribed metastatic sites.

Citations

Citations to this article as recorded by  
  • Cardiac Neuroendocrine Tumor Metastases on68Ga-DOTATATE PET/CT: Identification and Prognostic Significance
    Hwan Lee, Ahmad S. Alhamshari, Vandan Patel, Abhijit Bhattaru, Chaitanya Rojulpote, Mahesh K. Vidula, Daniel A. Pryma, Paco E. Bravo
    Journal of Nuclear Medicine.2024; 65(11): 1745.     CrossRef
  • Atypical Cardiac Location of Melanoma of Unknown Origin
    Agnieszka Styczeń, Mariusz Kozak, Marta Karaś-Głodek, Elżbieta Czekajska-Chehab, Andrzej Tomaszewski, Andrzej Wysokiński, Tomasz Zapolski
    Medicina.2021; 57(2): 107.     CrossRef
  • Cardiac Metastases in Patients with Neuroendocrine Tumours: Clinical Features, Therapy Outcomes, and Prognostic Implications
    Man Liu, Eleni Armeni, Shaunak Navalkissoor, Joseph Davar, Luke Sullivan, Charlotte Leigh, Luke Furtado O’Mahony, Aimee Hayes, Dalvinder Mandair, Jie Chen, Martyn Caplin, Christos Toumpanakis
    Neuroendocrinology.2021; 111(10): 907.     CrossRef
  • A concealed carcinoid cardiac metastasis uncovered by comprehensive cardiovascular magnetic resonance-based tissue characterization: a case report
    Georgios Georgiopoulos, Panagiota Mitropoulou, Pier Giorgio Masci, Juerg Schwitter, Khan Tina, Voges Inga, Raisi Estabragh Zahra, Minguito Carazo Carlos, Thomson Ross
    European Heart Journal - Case Reports.2020; 4(6): 1.     CrossRef
  • A Multimodal Approach to Evaluate for Cardiac Metastasis in a Case of Non-Small Cell Lung Cancer
    Nadeem Bilani, Leah Elson, Felipe Martinez, Diego Sadler, Zeina Nahleh, Elizabeth Elimimian, Evan Alley
    Case Reports in Oncology.2020; 13(1): 212.     CrossRef
  • Identification of multiple cardiac metastases from nonsmall-cell lung cancer by 18F-FDG PET/CT
    Shengming Deng, Bin Zhang, Jihui Li, Shibiao Sang, Wei Zhang
    Medicine.2018; 97(49): e12868.     CrossRef
  • 12,104 View
  • 67 Download
  • 6 Crossref
Close layer
Review Article
Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer
Fariz Nurwidya, Fumiyuki Takahashi, Akiko Murakami, Kazuhisa Takahashi
Cancer Res Treat. 2012;44(3):151-156.   Published online September 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.3.151
AbstractAbstract PDFPubReaderePub
Among all types of cancer, incidence of lung cancer remains the highest with regard to cancer-related mortality. Problems contributing to recurrence of the disease include metastasis and drug resistance. Mounting evidence has demonstrated involvement of epithelial mesenchymal transition (EMT) in cancer progression. EMT is a critical mechanism ensuring tissue remodeling during morphogenesis of multicellular organisms. Therefore, understanding of the biology of this process for identification of potential EMT-targeted therapeutic strategies for the benefit cancer patients is necessary. This review describes recent evidence of EMT involvement in drug resistance and metastasis of cancers, with an emphasis on lung cancer.

Citations

Citations to this article as recorded by  
  • DRMref: comprehensive reference map of drug resistance mechanisms in human cancer
    Xiaona Liu, Jiahao Yi, Tina Li, Jianguo Wen, Kexin Huang, Jiajia Liu, Grant Wang, Pora Kim, Qianqian Song, Xiaobo Zhou
    Nucleic Acids Research.2024; 52(D1): D1253.     CrossRef
  • Exploring the influence of microgravity on chemotherapeutic drug response in cancer: Unveiling new perspectives
    Preksha Manish Vora, Sudharshan Prabhu
    Journal of Cellular and Molecular Medicine.2024;[Epub]     CrossRef
  • Abemaciclib-induced epithelial-mesenchymal transition mediated by cyclin-dependent kinase 4/6 independent of cell cycle arrest pathway
    Tomoyo Yoshimori, Masashi Kawami, Yuta Kumagai, Sorahito Futatsugi, Ryoko Yumoto, Yasuo Uchida, Mikihisa Takano
    The International Journal of Biochemistry & Cell Biology.2024; 172: 106601.     CrossRef
  • SERPING1 Reduces Cell Migration via ERK‐MMP2‐MMP‐9 Cascade in Sorafenib‐ Resistant Hepatocellular Carcinoma
    Ching‐Chuan Hsieh, Yuh‐Harn Wu, Yi‐Li Chen, Chun‐I Wang, Chao‐Jen Li, I‐Hsiu Liu, Chen‐Wei Chou, Yang‐Hsiang Lin, Po‐Shuan Huang, Te‐Chia Huang, Cheng‐Yi Chen
    Environmental Toxicology.2024;[Epub]     CrossRef
  • Overcoming AZD9291 Resistance and Metastasis of NSCLC via Ferroptosis and Multitarget Interference by Nanocatalytic Sensitizer Plus AHP‐DRI‐12
    Liting Wang, Hao Fu, Liwei Song, Zhihua Wu, Jian Yu, Qianqian Guo, Chuanrong Chen, Xupeng Yang, Jiali Zhang, Quan Wang, Yourong Duan, Yunhai Yang
    Small.2023;[Epub]     CrossRef
  • Pomiferin targets SERCA, mTOR, and P-gp to induce autophagic cell death in apoptosis-resistant cancer cells, and reverses the MDR phenotype in cisplatin-resistant tumors in vivo
    Yuan-Qing Qu, Lin-Lin Song, Su-Wei Xu, Margaret Sum Yee Yu, Onat Kadioglu, Francesco Michelangeli, Betty Yuen Kwan Law, Thomas Efferth, Christopher Wai-Kei Lam, Vincent Kam Wai Wong
    Pharmacological Research.2023; 191: 106769.     CrossRef
  • Inferring ligand-receptor cellular networks from bulk and spatial transcriptomic datasets with BulkSignalR
    Jean-Philippe Villemin, Laia Bassaganyas, Didier Pourquier, Florence Boissière, Simon Cabello-Aguilar, Evelyne Crapez, Rita Tanos, Emmanuel Cornillot, Andrei Turtoi, Jacques Colinge
    Nucleic Acids Research.2023; 51(10): 4726.     CrossRef
  • RGMb impacts partial epithelial‐mesenchymal transition and BMP2‐Induced ID mRNA expression independent of PD‐L2 in nonsmall cell lung cancer cells
    Sofie Rahbek Dorset, Tina Fuglsang Daugaard, Trine Vilsbøll Larsen, Anders Lade Nielsen
    Cell Biology International.2023; 47(11): 1799.     CrossRef
  • The Impacts and Changes Related to the Cancer Drug Resistance Mechanism
    Prachi Varshney, Vishal Sharma, Devdhar Yadav, Yogesh Kumar, Amit Singh, Naga Rani Kagithala, Pramod Kumar Sharma, Omji Porwal, Neeraj Kumar Fuloria, Pradeep Kumar Sharma, Ashok Kumar Gupta, Koteswara Rao GSN
    Current Drug Metabolism.2023; 24(12): 787.     CrossRef
  • Quercetin Inhibits the Epithelial to Mesenchymal Transition through Suppressing Akt Mediated Nuclear Translocation of β-Catenin in Lung Cancer Cell Line
    Perumal Elumalai, Devaraj Ezhilarasan, Subramanian Raghunandhakumar
    Nutrition and Cancer.2022; 74(5): 1894.     CrossRef
  • Resistance to cisplatin in human lung adenocarcinoma cells: effects on the glycophenotype and epithelial to mesenchymal transition markers
    Leonardo Marques da Fonseca, Vanessa Amil da Silva, Kelli Monteiro da Costa, Jhenifer Santos dos Reis, José Osvaldo Previato, Lucia Mendonça Previato, Leonardo Freire-de-Lima
    Glycoconjugate Journal.2022; 39(2): 247.     CrossRef
  • Study on the mechanism of Cortex Lycii on lung cancer based on network pharmacology combined with experimental validation
    Zhenhui Guo, Heng Yin, Tong Wu, Shaofeng Wu, Lingyun Liu, Lei Zhang, Yanli He, Ren Zhang, Na Liu
    Journal of Ethnopharmacology.2022; 293: 115280.     CrossRef
  • Statistical parametrization of cell cytoskeleton reveals lung cancer cytoskeletal phenotype with partial EMT signature
    Arkaprabha Basu, Manash K. Paul, Mitchel Alioscha-Perez, Anna Grosberg, Hichem Sahli, Steven M. Dubinett, Shimon Weiss
    Communications Biology.2022;[Epub]     CrossRef
  • Fangchinoline targets epithelial–mesenchymal transition process by modulating activation of multiple cell‐signaling pathways
    Young Y. Jung, Arunachalam Chinnathambi, Tahani A. Alahmadi, Sulaiman A. Alharbi, Alan P. Kumar, Gautam Sethi, Kwang S. Ahn
    Journal of Cellular Biochemistry.2022; 123(7): 1222.     CrossRef
  • Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer
    Kuojun Zhang, Kaizhen Wang, Xiangyu Zhang, Zhenlong Qian, Wenbo Zhang, Xiao Zheng, Jiaying Wang, Yin Jiang, Wanheng Zhang, Zhiyu Lu, Haiping Hao, Sheng Jiang
    Journal of Medicinal Chemistry.2022; 65(11): 7746.     CrossRef
  • Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting
    Rahul Rimal, Prachi Desai, Rasika Daware, Aisa Hosseinnejad, Jai Prakash, Twan Lammers, Smriti Singh
    Advanced Drug Delivery Reviews.2022; 189: 114504.     CrossRef
  • Crizotinib attenuates cancer metastasis by inhibiting TGFβ signaling in non-small cell lung cancer cells
    Soonbum Park, Eun A Cho, Jung Nyeo Chun, Da Young Lee, Sanghoon Lee, Mi Yeon Kim, Sang Mun Bae, Su In Jo, So Hee Lee, Hyun Ho Park, Tae Min Kim, Insuk So, Sang-Yeob Kim, Ju-Hong Jeon
    Experimental & Molecular Medicine.2022; 54(8): 1225.     CrossRef
  • The actin cytoskeleton: Morphological changes in pre- and fully developed lung cancer
    Arkaprabha Basu, Manash K. Paul, Shimon Weiss
    Biophysics Reviews.2022;[Epub]     CrossRef
  • Challenges and Opportunities in Cancer Drug Resistance
    Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, Paul D. Smith
    Chemical Reviews.2021; 121(6): 3297.     CrossRef
  • Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I
    Archana Upadhya, Khushwant S. Yadav, Ambikanandan Misra
    Expert Opinion on Drug Delivery.2021; 18(1): 73.     CrossRef
  • Design, Synthesis and Biological Evaluation of New Pyrimidine Derivatives as Anticancer Agents
    Valentina Noemi Madia, Alice Nicolai, Antonella Messore, Alessandro De Leo, Davide Ialongo, Valeria Tudino, Francesco Saccoliti, Daniela De Vita, Luigi Scipione, Marco Artico, Samanta Taurone, Ludovica Taglieri, Roberto Di Santo, Susanna Scarpa, Roberta C
    Molecules.2021; 26(3): 771.     CrossRef
  • Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis
    Arpita Datta, Shuo Deng, Vennila Gopal, Kenneth Chun-Hong Yap, Clarissa Esmeralda Halim, Mun Leng Lye, Mei Shan Ong, Tuan Zea Tan, Gautam Sethi, Shing Chuan Hooi, Alan Prem Kumar, Celestial T. Yap
    Cancers.2021; 13(8): 1882.     CrossRef
  • ARHGAP10 inhibits the epithelial–mesenchymal transition of non-small cell lung cancer by inactivating PI3K/Akt/GSK3β signaling pathway
    Lan-Lan Lin, Fan Yang, Dong-Huan Zhang, Cong Hu, Sheng Yang, Xiang-Qi Chen
    Cancer Cell International.2021;[Epub]     CrossRef
  • Roles and Regulation of Growth differentiation factor-15 in the Immune and tumor microenvironment
    Rathna Silviya Lodi, Bin Yu, Lin Xia, Fang Liu
    Human Immunology.2021; 82(12): 937.     CrossRef
  • Potential function of oxymatrine as a novel suppressor of epithelial-to-mesenchymal transition in lung tumor cells
    Young Yun Jung, Seung Ho Baek, Acharan S. Narula, Ojas A. Namjoshi, Bruce E. Blough, Kwang Seok Ahn
    Life Sciences.2021; 284: 119893.     CrossRef
  • Prognostic value of epithelial‐mesenchymal transition‐inducing transcription factors in head and neck squamous cell carcinoma: A meta‐analysis
    Yuehan Wan, Haichao Liu, Ming Zhang, Zhengxian Huang, Han Zhou, Yue Zhu, Yifan Tao, Nan Xie, Xiqiang Liu, Jinsong Hou, Cheng Wang
    Head & Neck.2020; 42(5): 1067.     CrossRef
  • Fucoidan increased the sensitivity to gefitinib in lung cancer cells correlates with reduction of TGFβ-mediated Slug expression
    Wei-Lun Qiu, Ai-Jung Tseng, Hsien-Yeh Hsu, Wei-Hung Hsu, Zhi-Hu Lin, Wei-Jyun Hua, Tung-Yi Lin
    International Journal of Biological Macromolecules.2020; 153: 796.     CrossRef
  • Precision Management of Advanced Non–Small Cell Lung Cancer
    Ching-Yao Yang, James Chih-Hsin Yang, Pan-Chyr Yang
    Annual Review of Medicine.2020; 71(1): 117.     CrossRef
  • Postpartum breast cancer progression is driven by semaphorin 7a-mediated invasion and survival
    Sarah E. Tarullo, Ryan C. Hill, Kirk C. Hansen, Fariba Behbod, Virginia F. Borges, Andrew C. Nelson, Traci R. Lyons
    Oncogene.2020; 39(13): 2772.     CrossRef
  • Uptake of collagen type I via macropinocytosis cause mTOR activation and anti-cancer drug resistance
    Shota Yamazaki, Yinghan Su, Ami Maruyama, Hideki Makinoshima, Jun Suzuki, Masahiro Tsuboi, Koichi Goto, Atsushi Ochiai, Genichiro Ishii
    Biochemical and Biophysical Research Communications.2020; 526(1): 191.     CrossRef
  • LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers
    Chen Chen, Wei-Ran Liu, Bin Zhang, Lian-Min Zhang, Chen-Guang Li, Chang Liu, Hua Zhang, Yan-Song Huo, Yu-Chen Ma, Peng-Fei Tian, Qi Qi, Jing-Jing Li, Zhe Tang, Zhen-Fa Zhang, Giuseppe Giaccone, Dong-Sheng Yue, Chang-Li Wang
    Cancer Letters.2020; 486: 58.     CrossRef
  • Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo
    Ning Liu, Mingxing Ma, Na Qu, Ruizhe Wang, Hao Chen, Fangzhu Hu, Song Gao, Fengping Shan
    International Immunopharmacology.2020; 86: 106718.     CrossRef
  • Drug resistance in cancer: mechanisms and tackling strategies
    Tanweer Haider, Vikas Pandey, Nagma Banjare, Prem N. Gupta, Vandana Soni
    Pharmacological Reports.2020; 72(5): 1125.     CrossRef
  • Targeting Notch signaling pathway as an effective strategy in overcoming drug resistance in ovarian cancer
    Maryam Akbarzadeh, Shabnam Akbarzadeh, Maryam Majidinia
    Pathology - Research and Practice.2020; 216(11): 153158.     CrossRef
  • MicroRNA-7 targets T-Box 2 to inhibit epithelial-mesenchymal transition and invasiveness in glioblastoma multiforme
    Chih-Ming Pan, Kai-Hsiang Chan, Chao-Hsuan Chen, Chia-Ing Jan, Ming-Chao Liu, Chien-Min Lin, Der-Yang Cho, Wan-Chen Tsai, Yen-Tse Chu, Cheng-Hsin Cheng, Hao-Yu Chuang, Shao-Chih Chiu
    Cancer Letters.2020; 493: 133.     CrossRef
  • Tumor Clonality and Resistance Mechanisms in EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Implications for Therapeutic Sequencing
    Shinji Kohsaka, Mark Petronczki, Flavio Solca, Makoto Maemondo
    Future Oncology.2019; 15(6): 637.     CrossRef
  • Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma
    Hee Sang Hwang, Heounjeong Go, Ja-Min Park, Sun Young Yoon, Jae-Lyun Lee, Se Un Jeong, Yong Mee Cho
    Laboratory Investigation.2019; 99(5): 659.     CrossRef
  • PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma
    Honghai Ma, Alexandra Hockla, Christine Mehner, Matt Coban, Niv Papo, Derek C. Radisky, Evette S. Radisky
    Scientific Reports.2019;[Epub]     CrossRef
  • MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells
    Mingqi Wang, Renwen Zhang, Shu Zhang, Rui Xu, Qing Yang
    Gene.2019; 700: 110.     CrossRef
  • Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells
    Masashi Kawami, Risako Harada, Takamichi Ojima, Yohei Yamagami, Ryoko Yumoto, Mikihisa Takano
    Toxicology.2019; 424: 152231.     CrossRef
  • Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids
    Qingmei Ye, Kai Liu, Qun Shen, Qingyue Li, Jinghui Hao, Fangxuan Han, Ren-Wang Jiang
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • BTBD7 Downregulates E-Cadherin and Promotes Epithelial-Mesenchymal Transition in Lung Cancer
    Jie Shu, Lin Wang, Fei Han, Yubin Chen, Shunjun Wang, Fanyan Luo
    BioMed Research International.2019; 2019: 1.     CrossRef
  • Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition
    Fei-Fei FENG, Peng CHENG, Chao SUN, Hui WANG, Wei WANG
    Chinese Journal of Natural Medicines.2019; 17(10): 768.     CrossRef
  • The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior
    Veronika Skarkova, Marketa Krupova, Barbora Vitovcova, Adam Skarka, Petra Kasparova, Petr Krupa, Vera Kralova, Emil Rudolf
    International Journal of Molecular Sciences.2019; 20(18): 4630.     CrossRef
  • Bidirectional and Opposite Effects of Naïve Mesenchymal Stem Cells Ontumor Growth and Progression
    Faramarz Rahmatizadeh, Shiva Gholizadeh-Ghaleh Aziz, Khodadad Khodadadi, Maryam Lale Ataei, Esmaeil Ebrahimie, Jafar Soleimani Rad, Maryam Pashaiasl
    Advanced Pharmaceutical Bulletin.2019; 9(4): 539.     CrossRef
  • Estrogen receptors promote NSCLC progression by modulating the membrane receptor signaling network: a systems biology perspective
    Xiujuan Gao, Yue Cai, Zhuo Wang, Wenjuan He, Sisi Cao, Rong Xu, Hui Chen
    Journal of Translational Medicine.2019;[Epub]     CrossRef
  • CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma
    Gargi Maity, Arnab Ghosh, Vijayalaxmi Gupta, Inamul Haque, Sandipto Sarkar, Amlan Das, Kakali Dhar, Sneha Bhavanasi, Sumedha S. Gunewardena, Daniel D. Von Hoff, Sanku Mallik, Suman Kambhampati, Sushanta K. Banerjee, Snigdha Banerjee
    Molecular Cancer Therapeutics.2019; 18(4): 788.     CrossRef
  • Role of Cytomorphology in the Era of Liquid Biopsy
    Eduardo Clery, Pasquale Pisapia, Elena Vigliar, Umberto Malapelle, Claudio Bellevicine, Giancarlo Troncone, Fernando C. Schmitt
    Acta Cytologica.2019; 63(6): 497.     CrossRef
  • TGFβ pathway inhibition in the treatment of non-small cell lung cancer
    Pınar Ö. Eser, Pasi A. Jänne
    Pharmacology & Therapeutics.2018; 184: 112.     CrossRef
  • Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
    Shang-Gin Wu, Jin-Yuan Shih
    Molecular Cancer.2018;[Epub]     CrossRef
  • A bibenzyl from Dendrobium ellipsophyllum induces apoptosis in human lung cancer cells
    Anirut Hlosrichok, Somruethai Sumkhemthong, Boonchoo Sritularak, Pithi Chanvorachote, Chatchai Chaotham
    Journal of Natural Medicines.2018; 72(3): 615.     CrossRef
  • A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial–mesenchymal transition
    Yi-fan Zhao, Mei-ling Han, Ya-jie Xiong, Long Wang, Yao Fei, Xiao Shen, Ying Zhu, Zhong-qin Liang
    Acta Pharmacologica Sinica.2018; 39(6): 1034.     CrossRef
  • Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors
    Jens C. Hahne, Nicola Valeri
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • Bergamottin Suppresses Metastasis of Lung Cancer Cells through Abrogation of Diverse Oncogenic Signaling Cascades and Epithelial-to-Mesenchymal Transition
    Jeong-Hyeon Ko, Dongwoo Nam, Jae-Young Um, Sang Jung, Gautam Sethi, Kwang Ahn
    Molecules.2018; 23(7): 1601.     CrossRef
  • Lysyl hydroxylases are transcription targets for GATA3 driving lung cancer cell metastasis
    Wei Liu, Ting Zhang, Lixia Guo, Yuanyuan Wang, Yanan Yang
    Scientific Reports.2018;[Epub]     CrossRef
  • FOXC2 promotes epithelial–mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells
    Yuwen He, Hui Xie, Pengjiu Yu, Shunjun Jiang, Li Wei
    Cancer Chemotherapy and Pharmacology.2018; 82(6): 1049.     CrossRef
  • SPARC acts as a mediator of TGF‐β1 in promoting epithelial‐to‐mesenchymal transition in A549 and H1299 lung cancer cells
    Weichao Sun, Jianguo Feng, Qian Yi, Xichao Xu, Ying Chen, Liling Tang
    BioFactors.2018; 44(5): 453.     CrossRef
  • Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
    Tatsuya Nagano, Motoko Tachihara, Yoshihiro Nishimura
    Cells.2018; 7(11): 212.     CrossRef
  • Epigenetic suppression of E-cadherin expression by Snail2 during the metastasis of colorectal cancer
    Yue Hu, Mingrui Dai, Yayuan Zheng, Jiaxin Wu, Bin Yu, Haihong Zhang, Wei Kong, Hui Wu, Xianghui Yu
    Clinical Epigenetics.2018;[Epub]     CrossRef
  • Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance
    Yingjiao Xue, Shenda Hou, Hongbin Ji, Xiangkun Han
    Protein & Cell.2017; 8(3): 178.     CrossRef
  • Benzophenone-3 increases metastasis potential in lung cancer cells via epithelial to mesenchymal transition
    Preeyaporn Plaimee Phiboonchaiyanan, Kesarin Busaranon, Chuanpit Ninsontia, Pithi Chanvorachote
    Cell Biology and Toxicology.2017; 33(3): 251.     CrossRef
  • Molecular mechanisms of therapy resistance in solid tumors: chasing “moving” targets
    Laura J. Tafe
    Virchows Archiv.2017; 471(2): 155.     CrossRef
  • Duchesnea indicaextract suppresses the migration of human lung adenocarcinoma cells by inhibiting epithelial-mesenchymal transition
    Pei-Ni Chen, Shun-Fa Yang, Cheng-Chia Yu, Chin-Yin Lin, Shih-Han Huang, Shu-Chen Chu, Yih-Shou Hsieh
    Environmental Toxicology.2017; 32(8): 2053.     CrossRef
  • Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Byoung Soo Kwon, Ji Hyun Park, Woo Sung Kim, Joon Seon Song, Chang-Min Choi, Jin Kyung Rho, Jae Cheol Lee
    Tuberculosis and Respiratory Diseases.2017; 80(2): 187.     CrossRef
  • Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition
    Wei Lou, Yan Chen, Ke-ying Zhu, Huizi Deng, Tianhao Wu, Jun Wang
    Biological & Pharmaceutical Bulletin.2017; 40(8): 1306.     CrossRef
  • Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition
    Verena Tiran, Joerg Lindenmann, Luka Brcic, Ellen Heitzer, Stefanie Stanzer, Nassim Ghaffari Tabrizi-Wizsy, Elvira Stacher, Herbert Stoeger, Helmut H. Popper, Marija Balic, Nadia Dandachi
    Scientific Reports.2017;[Epub]     CrossRef
  • Clusterin modulates transdifferentiation of non-small-cell lung cancer
    Runsen Jin, Xingshi Chen, Dingpei Han, Xiaoying Luo, Hecheng Li
    BMC Cancer.2017;[Epub]     CrossRef
  • Growth Hormone and the Epithelial-to-Mesenchymal Transition
    Alison L Brittain, Reetobrata Basu, Yanrong Qian, John J Kopchick
    The Journal of Clinical Endocrinology & Metabolism.2017; 102(10): 3662.     CrossRef
  • Silencing NUDT21 Attenuates the Mesenchymal Identity of Glioblastoma Cells via the NF-κB Pathway
    Jia-Cheng Lou, Yu-Long Lan, Jin-Xia Gao, Bin-Bin Ma, Ting Yang, Zhong-Bo Yuan, Hong-Qiang Zhang, Ting-Zhun Zhu, Ning Pan, Song Leng, Gui-Jun Song, Bo Zhang
    Frontiers in Molecular Neuroscience.2017;[Epub]     CrossRef
  • Benzo(a)pyrene enhances the EMT-associated migration of lung adenocarcinoma A549 cells by upregulating Twist1
    Xi Chen, Hongbing Peng, Jian Xiao, Anqi Guan, Bin Xie, Bixiu He, Qiong Chen
    Oncology Reports.2017; 38(4): 2141.     CrossRef
  • Gankyrin promotes epithelial-mesenchymal transition and metastasis in NSCLC through forming a closed circle with IL-6/ STAT3 and TGF-β/SMAD3 signaling pathway
    Wu-ping Wang, Ying Sun, Qiang Lu, Jin-bo Zhao, Xue-jiao Wang, Zhao Chen, Yun-feng Ni, Ju-zheng Wang, Yong Han, Zhi-pei Zhang, Xiao-long Yan, Xiao-fei Li
    Oncotarget.2017; 8(4): 5909.     CrossRef
  • Surfactant-based drug delivery systems for treating drug-resistant lung cancer
    Prabhjot Kaur, Tarun Garg, Goutam Rath, R. S. R. Murthy, Amit K. Goyal
    Drug Delivery.2016; 23(3): 717.     CrossRef
  • Moscatilin inhibits epithelial-to-mesenchymal transition and sensitizes anoikis in human lung cancer H460 cells
    Kesarin Busaranon, Preeyaporn Plaimee, Boonchoo Sritularak, Pithi Chanvorachote
    Journal of Natural Medicines.2016; 70(1): 18.     CrossRef
  • SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinoma
    S Luanpitpong, J Li, A Manke, K Brundage, E Ellis, S L McLaughlin, P Angsutararux, N Chanthra, M Voronkova, Y C Chen, L Wang, P Chanvorachote, M Pei, S Issaragrisil, Y Rojanasakul
    Oncogene.2016; 35(22): 2824.     CrossRef
  • Endothelial Transdifferentiation of Tumor Cells Triggered by the Twist1‐Jagged1‐KLF4 Axis: Relationship between Cancer Stemness and Angiogenesis
    Hsiao-Fan Chen, Kou-Juey Wu, Silvia Brunelli
    Stem Cells International.2016;[Epub]     CrossRef
  • The attenuation of epithelial to mesenchymal transition and induction of anoikis by gigantol in human lung cancer H460 cells
    Thitita Unahabhokha, Pithi Chanvorachote, Varisa Pongrakhananon
    Tumor Biology.2016; 37(7): 8633.     CrossRef
  • Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner
    Sung-Hak Kim, Ravesanker Ezhilarasan, Emma Phillips, Daniel Gallego-Perez, Amanda Sparks, David Taylor, Katherine Ladner, Takuya Furuta, Hemragul Sabit, Rishi Chhipa, Ju Hwan Cho, Ahmed Mohyeldin, Samuel Beck, Kazuhiko Kurozumi, Toshihiko Kuroiwa, Ryoichi
    Cancer Cell.2016; 29(2): 201.     CrossRef
  • Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells
    Xin Liu, Li-Li Ban, Gang Luo, Zhi-Yao Li, Yun-Feng Li, Yong-Chun Zhou, Xi-Cai Wang, Cong-Guo Jin, Jia-Gui Ye, Ding-Ding Ma, Qing Xie, You-Guang Huang
    Anti-Cancer Drugs.2016; 27(5): 417.     CrossRef
  • ANGPTL4 Correlates with NSCLC Progression and Regulates Epithelial-Mesenchymal Transition via ERK Pathway
    Xiaoming Zhu, Xiaobin Guo, Sen Wu, Li Wei
    Lung.2016; 194(4): 637.     CrossRef
  • Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment
    Yang Ni, Jingwang Bi, Xin Ye, Weijun Fan, Guohua Yu, Xia Yang, Guanghui Huang, Wenhong Li, Jiao Wang, Xiaoying Han, Xiang Ni, Zhigang Wei, Mingyong Han, Aimin Zheng, Min Meng, Guoliang Xue, Liang Zhang, Chao Wan
    Medicine.2016; 95(25): e3998.     CrossRef
  • Effects of RECQ1 helicase silencing on non-small cell lung cancer cells
    Lin Li, Mingyang Gao, Bo Song, Hua Zhang, Yanfu Wang
    Biomedicine & Pharmacotherapy.2016; 83: 1227.     CrossRef
  • Gigantol Inhibits Epithelial to Mesenchymal Process in Human Lung Cancer Cells
    Thitita Unahabhokha, Pithi Chanvorachote, Boonchoo Sritularak, Jutarat Kitsongsermthon, Varisa Pongrakhananon, Yoshiki Mukudai
    Evidence-Based Complementary and Alternative Medicine.2016;[Epub]     CrossRef
  • DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive properties
    A C Little, D Sham, M Hristova, K Danyal, D E Heppner, R A Bauer, L M Sipsey, A Habibovic, A van der Vliet
    Oncogenesis.2016; 5(10): e261.     CrossRef
  • Long range personalized cancer treatment strategies incorporating evolutionary dynamics
    Chen-Hsiang Yeang, Robert A. Beckman
    Biology Direct.2016;[Epub]     CrossRef
  • Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells
    Mei-ling Han, Yi-fan Zhao, Cai-hong Tan, Ya-jie Xiong, Wen-juan Wang, Feng Wu, Yao Fei, Long Wang, Zhong-qin Liang
    Acta Pharmacologica Sinica.2016; 37(12): 1606.     CrossRef
  • Highly Expressed Integrin-α8 Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse
    Jiyeon Ryu, Youngil Koh, Hyejoo Park, Dae Yoon Kim, Dong Chan Kim, Ja Min Byun, Hyun Jung Lee, Sung-Soo Yoon
    Molecules and Cells.2016; 39(12): 898.     CrossRef
  • Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells
    SHANG-HSUN TSOU, MING-HUNG HOU, LIH-CHING HSU, TZER-MING CHEN, YEN-HUI CHEN
    International Journal of Molecular Medicine.2016; 37(1): 233.     CrossRef
  • Overexpression of PAD4 suppresses drug resistance of NSCLC cell lines to gefitinib through inhibiting Elk1-mediated epithelial-mesenchymal transition
    QIONG DUAN, CUI PANG, NING CHANG, JU ZHANG, WENCHAO LIU
    Oncology Reports.2016; 36(1): 551.     CrossRef
  • Iron induces cancer stem cells and aggressive phenotypes in human lung cancer cells
    Pithi Chanvorachote, Sudjit Luanpitpong
    American Journal of Physiology-Cell Physiology.2016; 310(9): C728.     CrossRef
  • miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer
    Fa-yong Hu, Xiao-nian Cao, Qin-zi Xu, Yu Deng, Sen-yan Lai, Jing Ma, Jun-bo Hu
    Journal of Huazhong University of Science and Technology [Medical Sciences].2016; 36(6): 839.     CrossRef
  • Side population cells from long-term passage non-small cell lung cancer cells display loss of cancer stem cell-like properties and chemoradioresistance
    Hao Gu, Xin-Yu Wu, Rui-Tai Fan, Xin Wang, You-Zhong Guo, Rui Wang
    Oncology Letters.2016; 12(4): 2886.     CrossRef
  • Ubiquilin1 represses migration and epithelial-to-mesenchymal transition of human non-small cell lung cancer cells
    P P Shah, W W Lockwood, K Saurabh, Z Kurlawala, S P Shannon, S Waigel, W Zacharias, L J Beverly
    Oncogene.2015; 34(13): 1709.     CrossRef
  • AEG-1 3′-untranslated region functions as a ceRNA in inducing epithelial–mesenchymal transition of human non-small cell lung cancer by regulating miR-30a activity
    Kunmei Liu, Le Guo, Yongjian Guo, Bo Zhou, Tong Li, Hua Yang, Runting Yin, Tao Xi
    European Journal of Cell Biology.2015; 94(1): 22.     CrossRef
  • SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial–mesenchymal transition via ERK and PI3K/AKT pathway
    Peng Yang, Gang Wang, Hongjun Huo, Qiang Li, Yan Zhao, Yuanhang Liu
    Medical Oncology.2015;[Epub]     CrossRef
  • Extracellular vesicles in the biology of brain tumour stem cells – Implications for inter-cellular communication, therapy and biomarker development
    Ichiro Nakano, Delphine Garnier, Mutsuko Minata, Janusz Rak
    Seminars in Cell & Developmental Biology.2015; 40: 17.     CrossRef
  • Slug contributes to cancer progression by direct regulation of ERα signaling pathway
    YOUQIANG LI, YANYUAN WU, THOMAS C. ABBATIELLO, WARREN L. WU, JU RI KIM, MARIANNA SARKISSYAN, SUREN SARKISSYAN, SEYUNG S. CHUNG, YAHYA ELSHIMALI, JAYDUTT V. VADGAMA
    International Journal of Oncology.2015; 46(4): 1461.     CrossRef
  • Integrin-Linked Kinase, Snail and Multidrug Resistance Protein 1: Three concordant players in the progression of non-small cell lung cancer
    Dalia M. Abd El-Rehim, Manal I. Abd-Elghany, Maiiada H. Nazmy
    Journal of the Egyptian National Cancer Institute.2015; 27(3): 129.     CrossRef
  • Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
    Vera Hirsh
    BioDrugs.2015; 29(3): 167.     CrossRef
  • Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid
    Gianfranco Baronzio, Gurdev Parmar, Miriam Baronzio
    Frontiers in Oncology.2015;[Epub]     CrossRef
  • Loss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2/neu expression
    Young San Ko, Sung Jin Cho, Jinju Park, Younghoon Kim, Yong Joon Choi, Jung-Soo Pyo, Bo Gun Jang, Jong-Wan Park, Woo Ho Kim, Byung Lan Lee
    British Journal of Cancer.2015; 113(8): 1186.     CrossRef
  • Epigallocatechin-3-gallate inhibits nicotine-induced migration and invasion by the suppression of angiogenesis and epithelial-mesenchymal transition in non-small cell lung cancer cells
    JINGLI SHI, FEI LIU, WENZHANG ZHANG, XIN LIU, BIHUA LIN, XUDONG TANG
    Oncology Reports.2015; 33(6): 2972.     CrossRef
  • Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival
    YAO LU, GUO-FENG GUAN, JIE CHEN, BIN HU, CONG SUN, QIONG MA, YAN-HUA WEN, XIU-CHUN QIU, YONG ZHOU
    Oncology Letters.2015; 10(4): 2123.     CrossRef
  • Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma
    Kian Ngiap Chua, Li Ren Kong, Wen Jing Sim, Hsien Chun Ng, Weijie Richard Ong, Jean Paul Thiery, Hung Huynh, Boon Cher Goh
    Oncotarget.2015; 6(30): 29991.     CrossRef
  • Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition
    Roberto Gomez-Casal, Michael W. Epperly, Hong Wang, David A. Proia, Joel S. Greenberger, Vera Levina
    Oncotarget.2015; 6(42): 44306.     CrossRef
  • Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment
    Hye-Ryoun Kim, Jae Chol Lee, Young-Chul Kim, Kyu-Sik Kim, In-Jae Oh, Sung Yong Lee, Tae Won Jang, Min Ki Lee, Kyeong-Cheol Shin, Gwan Ho Lee, Jeong-Seon Ryu, Seung Hoon Jang, Ji Woong Son, Jeong Eun Lee, Sun Young Kim, Hee Joung Kim, Kye Young Lee
    Lung Cancer.2014; 83(2): 252.     CrossRef
  • GPI/AMF inhibition blocks the development of the metastatic phenotype of mature multi-cellular tumor spheroids
    Juan Carlos Gallardo-Pérez, Nadia Alejandra Rivero-Segura, Alvaro Marín-Hernández, Rafael Moreno-Sánchez, Sara Rodríguez-Enríquez
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2014; 1843(6): 1043.     CrossRef
  • Expression of HMGA2 in bladder cancer and its association with epithelial‐to‐mesenchymal transition
    X. Ding, Y. Wang, X. Ma, H. Guo, X. Yan, Q. Chi, J. Li, Y. Hou, C. Wang
    Cell Proliferation.2014; 47(2): 146.     CrossRef
  • Vimentin silencing effect on invasive and migration characteristics of doxorubicin resistant MCF-7 cells
    Okan Tezcan, Ufuk Gündüz
    Biomedicine & Pharmacotherapy.2014; 68(3): 357.     CrossRef
  • Molecular characterization of scant lung tumor cells using iron-oxide nanoparticles and micro-nuclear magnetic resonance
    Arezou A. Ghazani, Melina Pectasides, Amita Sharma, Cesar M. Castro, Mari Mino-Kenudson, Hakho Lee, Jo-Anne O. Shepard, Ralph Weissleder
    Nanomedicine: Nanotechnology, Biology and Medicine.2014; 10(3): 661.     CrossRef
  • Triclosan Potentiates Epithelial-To-Mesenchymal Transition in Anoikis-Resistant Human Lung Cancer Cells
    Thidarat Winitthana, Somsong Lawanprasert, Pithi Chanvorachote, Aamir Ahmad
    PLoS ONE.2014; 9(10): e110851.     CrossRef
  • Rubus idaeus L Inhibits Invasion Potential of Human A549 Lung Cancer Cells by Suppression Epithelial-to-Mesenchymal Transition and Akt Pathway In Vitro and Reduces Tumor Growth In Vivo
    Shu-Chen Chu, Yih-Shou Hsieh, Li-Sung Hsu, Kuo-Shuen Chen, Chien-Cheng Chiang, Pei-Ni Chen
    Integrative Cancer Therapies.2014; 13(3): 259.     CrossRef
  • The inhibitory effect of anthocyanins on Akt on invasion and epithelial-mesenchymal transition is not associated with the anti-EGFR effect of the anthocyanins
    JING NAN LU, WON SUP LEE, MIN JEONG KIM, JEONG WON YUN, JI HYUN JUNG, SANG MI YI, JAE-HOON JEONG, HYE JUNG KIM, YUNG HYUN CHOI, GON-SUP KIM, CHUNG HO RYU, SUNG CHUL SHIN
    International Journal of Oncology.2014; 44(5): 1756.     CrossRef
  • Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer
    Tim N. Beck, Adaeze J. Chikwem, Nehal R. Solanki, Erica A. Golemis
    Physiological Genomics.2014; 46(19): 699.     CrossRef
  • Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivo
    YILI HAN, YONG LUO, JIAHUI ZHAO, MINGCHUAN LI, YONGGUANG JIANG
    Oncology Letters.2014; 8(4): 1618.     CrossRef
  • YAP-Induced Resistance of Cancer Cells to Antitubulin Drugs Is Modulated by a Hippo-Independent Pathway
    Yulei Zhao, Prem Khanal, Paul Savage, Yi-Min She, Terry D. Cyr, Xiaolong Yang
    Cancer Research.2014; 74(16): 4493.     CrossRef
  • Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis
    Jie Xu, Cai-feng Yue, Wei-hua Zhou, Yuan-min Qian, Yan Zhang, Shao-wu Wang, An-wen Liu, Quentin Liu
    Journal of Translational Medicine.2014;[Epub]     CrossRef
  • Ezrin promotes invasion and migration of the MG63 osteosarcoma cell
    Jian Zhang, Jianhong Zuo, Mingsheng Lei, Song Wu, Xiaofang Zang, Chaoyue Zhang
    Chinese Medical Journal.2014; 127(10): 1954.     CrossRef
  • Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
    D Gonzalez de Castro, P A Clarke, B Al-Lazikani, P Workman
    Clinical Pharmacology & Therapeutics.2013; 93(3): 252.     CrossRef
  • Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
    John R. Goffin, Kevin Zbuk
    Clinical Therapeutics.2013; 35(9): 1282.     CrossRef
  • Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
    Sílvia Cufí, Rosa Bonavia, Alejandro Vazquez-Martin, Cristina Oliveras-Ferraros, Bruna Corominas-Faja, Elisabet Cuyàs, Begoña Martin-Castillo, Enrique Barrajón-Catalán, Joana Visa, Antonio Segura-Carretero, Jorge Joven, Joaquim Bosch-Barrera, Vicente Mico
    Scientific Reports.2013;[Epub]     CrossRef
  • Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells
    Sílvia Cufí, Rosa Bonavia, Alejandro Vazquez-Martin, Bruna Corominas-Faja, Cristina Oliveras-Ferraros, Elisabet Cuyàs, Begoña Martin-Castillo, Enrique Barrajón-Catalán, Joana Visa, Antonio Segura-Carretero, Joaquim Bosch-Barrera, Jorge Joven, Vicente Mico
    Food and Chemical Toxicology.2013; 60: 360.     CrossRef
  • Rubus idaeus L. reverses epithelial-to-mesenchymal transition and suppresses cell invasion and protease activities by targeting ERK1/2 and FAK pathways in human lung cancer cells
    Yih-Shou Hsieh, Shu-Chen Chu, Li-Sung Hsu, Kuo-Shuen Chen, Ming-Tsung Lai, Chia-Heng Yeh, Pei-Ni Chen
    Food and Chemical Toxicology.2013; 62: 908.     CrossRef
  • Alteration of the E-cadherin/β-Catenin Complex Predicts Poor Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment
    Seol Bong Yoo, Yu Jung Kim, Hyojin Kim, Yan Jin, Ping-Li Sun, Sanghoon Jheon, Jong Seok Lee, Jin-Haeng Chung
    Annals of Surgical Oncology.2013; 20(S3): 545.     CrossRef
  • Lung cancer stem cells: a biological and clinical perspective
    Ana Koren, Helena Motaln, Tanja Cufer
    Cellular Oncology.2013; 36(4): 265.     CrossRef
  • Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology
    Paul Workman, Bissan Al-Lazikani, Paul A Clarke
    Current Opinion in Pharmacology.2013; 13(4): 486.     CrossRef
  • Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
    Jae Cheol Lee, Seung Hun Jang, Kye Young Lee, Young-Chul Kim
    Cancer Research and Treatment.2013; 45(2): 79.     CrossRef
  • Stem cell-like ALDHbrightcellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin
    BRUNA COROMINAS-FAJA, Cristina Oliveras-Ferraros, ELISABET CUYÀS, Antonio Segura-Carretero, Jorge Joven, Begoña Martin-Castillo, ENRIQUE BARRAJÓN-CATALÁN, Vicente Micol, Joaquim Bosch-Barrera, JAVIERABEL MENENDEZ MENENDEZ
    Cell Cycle.2013; 12(21): 3390.     CrossRef
  • Menadione (Vitamin K3) Induces Apoptosis of Human Oral Cancer Cells and Reduces their Metastatic Potential by Modulating the Expression of Epithelial to Mesenchymal Transition Markers and Inhibiting Migration
    Shruthy Suresh, Dinesh Raghu, Devarajan Karunagaran
    Asian Pacific Journal of Cancer Prevention.2013; 14(9): 5461.     CrossRef
  • Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
    Silvia La Monica, Cristina Caffarra, Francesca Saccani, Elena Galvani, Maricla Galetti, Claudia Fumarola, Mara Bonelli, Andrea Cavazzoni, Daniele Cretella, Rita Sirangelo, Rita Gatti, Marcello Tiseo, Andrea Ardizzoni, Elisa Giovannetti, Pier Giorgio Petro
    PLoS ONE.2013; 8(10): e78656.     CrossRef
  • Analysis of Flora Distribution and Drug Resistance in Sputum Culture from Patients with Lung Cancer
    Feng Hao, Rui Ze Ma, Xue Yan Wang, Hui Jing Xu, Fang Fang, Li Zhang, Hui Zheng, Yu Xuan Zang, Yan Li
    Advanced Materials Research.2013; 641-642: 625.     CrossRef
  • 16,167 View
  • 189 Download
  • 130 Crossref
Close layer
Case Report
Metastatic Skin Lesions on Lower Extremities in a Patient with Recurrent Serous Papillary Ovarian Carcinoma: A Case Report and Literature Review
Moon-Kyung Kim, Seo-Hee Kim, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Jeoung-Won Lee, Je-Ho Lee, Duk-Soo Bae, Byoung-Gie Kim
Cancer Res Treat. 2012;44(2):142-145.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.142
AbstractAbstract PDFPubReaderePub
Clinical observation of skin metastasis in ovarian cancer cases is relatively uncommon. And distant metastatic skin lesions including the extremities are much rarer still as most metastatic skin lesions are located in the skin in the abdominal wall adjacent to where the primary ovarian tumors exist. We report the case of a 60-year-old woman who presented skin lesions on both lower extremities as a consequence of the metastasis of serous papillary adenocarcinoma of the ovary. She presented with erythematous and painful cutaneous nodules on both upper legs and in the inguinal area 42 months after initial diagnosis of ovarian cancer. Skin biopsy revealed metastasis of adenocarcinoma in the dermis. She was treated with surgical excision and systemic chemotherapy. Literature review has suggested that a combined modality approach including surgical excision and chemotherapy may be useful in the management of skin metastases due to ovarian cancer.

Citations

Citations to this article as recorded by  
  • Skin metastasis from ovarian cancer with somatic BRCA1 mutation: A case report and literature review
    Jingheng Zhang, Wenfeng He, Zhenhua Zhang, Hui Dong, Xiangyu Deng, Qinglian Wen, Dan Li
    Oncology Letters.2024;[Epub]     CrossRef
  • Metastasis of ovarian cancer to nasal skin and skin on the trunk: a rare case report
    Chen Chen, Ouyang Yingyao, Xiang Yan, He Qianru, Wang Hong, Chen Chen, Yang Lei
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • A Rare and Sinister Presentation of Cutaneous Metastasis over Right Lower Limb in a Case of Ovarian Carcinoma
    Preema Sinha, Parul Kamboj, Anamika Sinha, Juhi Sharma
    Journal of Marine Medical Society.2022; 24(2): 211.     CrossRef
  • Clinicopathologic features of cutaneous metastases from internal malignancies
    Hyeong Mok Kwon, Gyu Yeong Kim, Dong Hoon Shin, Young Kyung Bae
    Journal of Pathology and Translational Medicine.2021; 55(4): 289.     CrossRef
  • Rare Sites Metastasis in Ovarian Carcinoma: a Compilation of 3 Case Reports
    Megha Nandwani, Debabrata Barmon, Dimpy Begum, Amal C. Kataki
    Indian Journal of Surgical Oncology.2020; 11(1): 150.     CrossRef
  • Cutaneous metastasis of PD-L1 positive ovarian carcinoma
    Victoria Hastings, Jennifer McEachron, Marguax J. Kanis
    Gynecologic Oncology Reports.2020; 33: 100607.     CrossRef
  • PET/CT for Evaluation of Ovarian Cancer
    Jukka Kemppainen, Johanna Hynninen, Johanna Virtanen, Marko Seppänen
    Seminars in Nuclear Medicine.2019; 49(6): 484.     CrossRef
  • Cutaneous Metastases in Ovarian Cancer
    Isao Otsuka
    Cancers.2019; 11(9): 1292.     CrossRef
  • Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature
    Gina Nam, Young-mee Lim, Min Sun Cho, Junghye Lee, Yun Hwan Kim
    Obstetrics & Gynecology Science.2017; 60(6): 593.     CrossRef
  • Two independent incidences of skin metastases in the umbilicus and abdominal wall in ovarian serous adenocarcinoma
    Hongyan Cheng, Chunmei Gao, Runtong Zhang, Zhaojie Yang, Guiyu Zhang
    Medicine.2017; 96(49): e9118.     CrossRef
  • Cutaneous metastases from adenocarcinoma of the ovary
    Heidi H. McDonald, Milton R. Moore, Jeffrey J. Meffert
    JAAD Case Reports.2016; 2(5): 406.     CrossRef
  • Ovarian carcinoma presenting as cutaneous nasal metastasis
    Ana Marta António, João Vitor Alves, João Goulão, Elvira Bártolo
    Anais Brasileiros de Dermatologia.2016; 91(5 suppl 1): 101.     CrossRef
  • 11,887 View
  • 72 Download
  • 12 Crossref
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP